var title_f6_7_6256="Colostomy PI";
var content_f6_7_6256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 477px\">",
"   <div class=\"ttl\">",
"    Colostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 457px; height: 563px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts a colostomy, which may be necessary in some people with severe diverticulutis, Crohn's disease, or as part of surgery done for colon cancer. In some people, the colostomy is temporary. In other people, the colostomy may be permanent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6256=[""].join("\n");
var outline_f6_7_6256=null;
var title_f6_7_6257="Rupatadine: International drug information";
var content_f6_7_6257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rupatadine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alergoliber (ES)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2677741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Rupatadine Fumarate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3123379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2677742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2677744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;12 years and Adults: Oral: 10 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2677745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 10 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10504 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-197.136.42.3-B90BB4646D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6257=[""].join("\n");
var outline_f6_7_6257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369743\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677741\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3123379\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677742\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677744\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821148\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677745\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10504\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10504|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_7_6258="Acute GVHD follicular";
var content_f6_7_6258=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute graft-versus-host disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small, erythematous, follicularly-based macules and papules are present on the distal lower extremities in this patient with acute graft-versus-host disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6258=[""].join("\n");
var outline_f6_7_6258=null;
var title_f6_7_6259="Selenium sulfide: Pediatric drug information";
var content_f6_7_6259=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Selenium sulfide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"    see \"Selenium sulfide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/41/30356?source=see_link\">",
"    see \"Selenium sulfide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dandrex;",
"     </li>",
"     <li>",
"      Head &amp; Shoulders&reg; Clinical Strength [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; 2-in-1 [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Medicated [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Moisturizing [OTC];",
"     </li>",
"     <li>",
"      Selsun blue&reg; Normal to Oily [OTC];",
"     </li>",
"     <li>",
"      Tersi",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Versel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiseborrheic Agent, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Shampoos",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=see_link\">",
"      see \"Selenium sulfide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;2 years and Adults: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dandruff, seborrhea: Massage 5-10 mL into wet scalp, leave on scalp 2-3 minutes, rinse thoroughly and repeat application; alternatively, 5-10 mL of shampoo is applied and allowed to remain on scalp for 5-10 minutes before being rinsed off thoroughly without a repeat application; shampoo twice weekly for 2 weeks initially, then use once every 1-4 weeks as indicated depending upon control",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tinea versicolor: Apply the 2.5% lotion in a thin layer covering the body surface from the face to the knees; leave on skin for 10 minutes, then rinse thoroughly; apply every day for 7 days; then follow with monthly applications for 3 months to prevent recurrences",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, foam, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tersi: 2.25% (70 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lotion, topical: 2.5% (118 mL, 120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical: 1% (210 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dandrex: 1% (236 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Head &amp; Shoulders&reg; Clinical Strength: 1% (420 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Medicated: 1% (120 mL, 207 mL, 325 mL) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Moisturizing: 1% (207 mL, 325 mL) [contains aloe, moisturizers]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; Normal to Oily: 1% (207 mL, 325 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Shampoo, topical [with conditioner]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Selsun blue&reg; 2-in-1: 1% (207 mL, 325 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes foam",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: For external use only; avoid contact with eyes or acutely inflamed skin",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To treat itching and flaking of the scalp associated with dandruff; to control scalp seborrheic dermatitis; treatment of tinea versicolor",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F220450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Lethargy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, hair discoloration, unusual dryness or oiliness of scalp",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, garlic breath, vomiting following long-term use on damaged skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, itching, irritation, stinging (transient)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to selenium or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use on damaged skin to avoid any systemic toxicity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal. Safety in infants has not been established; avoid use in children &lt;2 years of age",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F220416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have not been conducted. Avoid use in pregnant women unless the potential benefit justifies the potential risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May block the enzymes involved in growth of epithelial tissue",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Not absorbed topically through intact skin, but can be absorbed topically through damaged skin",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/41/30356?source=see_link\">",
"      see \"Selenium sulfide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Remove all jewelry before using the lotion; wash hands thoroughly following application of the lotion; may discolor hair",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Lester RS, &ldquo;Topical Formulary for the Pediatrician,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1983, 30(4):749-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6259/abstract-text/6225068/pubmed\" id=\"6225068\" target=\"_blank\">",
"        6225068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12785 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.16.9.173-D52E307D49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6259=[""].join("\n");
var outline_f6_7_6259=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220420\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220421\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049833\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049829\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220408\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220397\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049836\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049835\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220450\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049839\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049828\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049827\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300034\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222893\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220405\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220416\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049826\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049838\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049832\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12785\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12785|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?33/49/34579?source=related_link\">",
"      Selenium sulfide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/41/30356?source=related_link\">",
"      Selenium sulfide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_7_6260="Malig nephroscl Light I";
var content_f6_7_6260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Light micrograph showing malignant nephrosclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph reveals fibrinoid necrosis in the preglomerular afferent arteriole (arrow) in malignant nephrosclerosis. The normal muscle layer of the media has been replaced by the fibrinoid material.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6260=[""].join("\n");
var outline_f6_7_6260=null;
var title_f6_7_6261="Reserpine: Patient drug information";
var content_f6_7_6261=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Reserpine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"     see \"Reserpine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702863",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to reserpine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Low mood (depression), ulcerative colitis, or ulcer disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701083",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are getting electroconvulsive shock therapy (ECT).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701043",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to tartrazine, talk with your doctor. Some products have tartrazine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel disease such as Crohn's disease or ulcerative colitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697222",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallstones, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in sex ability.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11443 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6261=[""].join("\n");
var outline_f6_7_6261=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030098\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030100\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030099\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030104\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030105\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030107\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030102\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030103\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030108\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030109\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=related_link\">",
"      Reserpine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_7_6262="ECG Mobitz type I AV block and inferior MI";
var content_f6_7_6262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1130px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Electrocardiogram (ECG) showing concurrent Mobitz type I (Wenckebach) atrioventricular (AV) block and inferior myocardial infarction (MI)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 87px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This rhythm strip shows a Mobitz type I (Wenckebach) atrioventricular block with 4:3 and 3:2 conduction and progressive prolongation of the PR intervals of conducted beats. The marked ST segment elevation suggests acute inferior wall ischemia or infarction that may be responsible for the arrhythmia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAClAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6P0tpjZX+Yfm+0SYXd15q/OZPPtMRg/Mc/N0+U1R0gH7Lfjzwc3EnzYHy1fmBEtoBL/Ec8fe+U0zrq29o/n37CW7P9tugY8L8uDnrxWXqTP8A8I4SIwW85OM/9NhWpCT9su/nGPl49OKyNQDf8I0AbgZ85PnwOf3wpPYqj/Ej6xNadpPt9oNny4bJz04p0Ly+Zd5iHD/J833vlFNnP+n2n7zAw3y+vHWktxiW8zcZy/t8vyigx+z8v1Gq8otLQrEu4uAwLdKp7pv+Eux5Y8v7GPmz/tmps4s7LF1t+dctkfNzVVsHxacXZXNoPlyP7xoZvTS970fcsM9x/Yt2WiXcPMwN3UZNTyvP9rscxpglt3PT5aoKpOj3m6/Y5MmDleOtW5wv2uw/0s8Fu6/N8tApRV38+/YsSNIWuwyKAIxt568Gs7TDOPD+nkInmbkyM8Y3Va3KJ77NzuHlrgFh8vDVR0rB8OWCi6KtuT5gwz96lccY2h849+zNMmT+2CFVdnkDJJ5+8aooZ/7P1f5I93my4GTyNoq1hf7YLfaWz5I+XcMH5jVBVVtP1YfbWXMsnO5ePlHtQEF+nfuN1Uz/AG3QMrHzMc9ePkrUtvtH2673rGE+XaRnnisfVEX7boJF82BLyCy/N8v0rTt9gv7o/bmbhflLrgcfShFVV+7j6Po/5iq7XC+H7M7I/M3R/KScdatzNc/21aqFi2+RKd3P95P/AK1ZnyN4esx/aDZzH829c9fpV2RY/wC2LY/b3/1EnG9fVPakOUbN/wDb3R9ihpIu/setjbDuNxLgZPpWmPtYFgNsPTnk8fLWTpCxm01kG+kANxJzvX0+laTJHmwH9oSDHT5154+lNbF1177/AMn2LFv5/wDad3kRfcj55/2qzNWNz/wik2Vi3ZHGT/fFXIFT+1Lv/TpM7I8jev8Ate1ZmqiM+FJv9NfqP41/vjjpQ9iaMf3sfWPRnQSm4FzDgRbcNk80im58y4ysOAfl688d6jlRPtcGbyQEbvl3rz+lIFjDXJN9JyefnX5ePpVHKlp8uz7j5ftJW1IEW/eM9cY2mq0f2n+35eIdnkDnnPWnFY/KtQL98bx829cn5T7VBGqHxBJi9kz5A+Xcvr9KTNYrR+j6PuTL9q/s254izvlx1/vmppjc+ZY4EWNx3df7jVXUJ/Ztzm8cjfJzvXj5z7U+dUMlj/psgy/GHXn5G9qAa1fz6PsTg3Hnzhli27BgjPPWs3RvtY8O22xYdwJ4Of75q4qL9puf9OkJKDguvHXnpVDRlT/hG7fdeyAZPzb15+c98U1uVFWh849H2Zpn7T/aa8RY8k5PPrUB+1fY9R3LD1fA55+WpTGn9ooftkgPlHC7l55+lVnVWtdTxeSfx8Bl4+X6UiY9Pl08yLU/tn2fSsCAf6RFnrxV1Bdf2vIcQ48hM9f7zVnakiG30n/Tpf8AXxYw68/pV1YgdYlxey/6hONy/wB5vajqaSXuff0fcb/p39mXu7yPMzJ646VamN359thYeSdx544qkY4jpt6DfylMvlt6+n0q1Msfn2ub2TOTtG9fm4+lNIzlv9/R9ippf2r+2dYyIvvR46/3Kuf6SbGDiHfvTPXGM1Q0tY/7a1kC6fdujz8y/wB36Va2xrp8GLtym9Pn3j19cUiqq99f9u9P7pcYXH2tDiPbsbPX1FVz9o+zX+RF959vXpjvUzKv2yPNy4bY3G4c8j2qqyIbPUP9KkA3Pkhhxx9KZlBbfL8xbIz/ANl6bxFnbHnr021dUXPnsT5WzaMdc5rOs0Q6XpYN1J0jx8w5+Xp0q6iD7Y4F1KW2jKZGB74xSWwVVq/n08yNjcnTyWEW/wBBnGM1FdfaP7csMCLb5UueueqU5kj/ALKbF1IU7uWGRz0zimXaKdd0/M7hvKlwMjn7ntQyofE/+3unkW4fO8+5z5ecjb19KkXz/s8ePL38Z64xUUSL513iZ8kjdyPl4/SkURiygBncJ8uG3DJ9KZi1f8PyJ/3/AJx/1fl4985rNsTcf2dc8RBvPlx1/vmtH5PtTfvm37RlMjGPXFZeniIaZebZ3K+fLubPIO80uppD4X6rp6mlMZvNtsbMFju/75PSljEv2iYnbt42/lTZQpltj5rZ3HbyOflNLEym5nUSEsu3I9OKZl0+X6mfrAuP7LQfu9/nJu9Mb60G+0fao/8AV+XtOfXNZmsLCNGj/fv5fnJh88n560W8n7XFulbzdh2jPUetI2l8C06y6eg0C58i53GMHLbMA/rSuJilpkpuDDd6dDUatAIbzErnlt+WPHHamOYDDYjzX2hhtO45PB6mgmzvt+HkeW6b8SrlLG/2fD7xQ6NO7OBbjA56E5q/L8T70yWZ/wCFe+K+vy/6MP7p6c11+lNqpstROLUsJ5No55NX5Dq3mWeRZ5JO4fNx8ppanTVgud3a69fI4/wp8RINX8aS6Je+HdZ0nUJ7f7Qn22EKHVRg9K6S/aL/AIRnmF9nnJ8pTn/XCuS1ddTT406BJi1/eWNzGG5xwobp1rpdQOq/8I7nFmT5qcfN/wA9RSu7MqFNKcLNbx6m3cOn9o2eYn3YfB2dBim28kHmX4W3lxv+ceWfm+UdKrTHVv7QswRZhcPkjd1xSwnWPMvTiy3B/lGG5+UUzH2a5d1t38xpmtxYWANpMV8xdi+UTg5qBpLceMMm2lMhsxz5R/vGnIdY+xWRxZFi65BDcfrUf/E1/wCEqxmy/wCPQc4b+8fekzeMUubVbS6kqSwHR71RZzgAyZBhPXmrlxJF9qss2svVsfuuny1QA1ddIuyWsush6N0596szjV/tVlk2Octn5W/u/WmRKKu9V16+RIZIftF7i1lyY1z+668NVLTJIf8AhHrH/RZiu5flEWT96rDDV/OvMtZbfLGPlb/a96z9JTWG8O2IjazByuMhs/e+tF9SoxXJ8S3j18mbHnxf2r/x7TFjCOfK6cms8TQ/YNWBs5yDJIceV/sirONW/tU82OPJGflb+8feqgXVRp+q4ay+/Ln5W/uj3pMmEUuq6dfMh1eWL7b4f/0Sbibj910+WtO3ng+33eLKcN8uT5PXisfVRq/2zQNz2Q/fdlb+735rVtxrH9oXWXsduF42t6fWhM0qRXs46rZ9X/N6FJJIToFmPsM/VOPJ96vSyw/21an7HNnyJefJ90rP26uugWgL2ecx4O1s9eO9XpV1b+2LU77LAhk42t6p7/ShMU0rvVfa6vsVNMkh+y6x/oku0TScGHGeKuNPDmwP2G4OOmIOny1m6b/azWms7WtA3nSDlW64+taKrqxFhmSzyBz8jf3frQnoOrFKb1X3vsT20sTancj7JKuUj5MXH8VZertCPCdwPssnBHAi77xzV+Aap/a13+8tNuyPA2t/te9ZWsJqn/CJzZktuozhTnG8e9DYqMV7WOq3j1ZvvNG15ADazZIb5jFwKXzIg1xm1lPPP7rrxUEqap9sg/fWmz5sjYf8aAmq5ux59qSfufIeOPrVXObljZarbu+/oK80LRWZ+xTYMg+XyeR8p5xUUckQ8QyD7NKD5A58rjrSGLVhDZAzWu8ON3yHptOe9RImpf8ACRy/vrfZ9nH8B/vfWk2axjG0veWz6vv6FhZYv7OuR9llI8yXjyuvzmpppIhJY/6LIfn4/d/d+RqqxxamNOuR51vkySlfkPHzn3qSSLU/MsMz2/Dnd8h5+Rvenclxjd+8uvV9vQmDx/abnFrL9wc+X168VQ0R4v8AhG7bNpIwBPyeXk/fNXgmo+fcbprcqUG0bD1596y9Fi1M+HLdUmt9+TyUP98+9F9Sopezeq3j1fZmz5kZv0H2eTPlnDeXwOelVi0Zs9TxbuD8/VOvy04x6j/aSET2+wRHcNh5OfrVd49R+yalmeDB34Gw8fL9aLkRitNV06vv6DdRMRt9J/0aT/XxY/d9PrV5Cg1iX9y3+oTnZ/tNWXqUWo/ZdJxcQ7hPFk7D/jV2OLUP7XlJuIMeQv8AyzP95velcuUVyfEuvfv6CM0f9mXv+iSdZPlMfXirUpjNxa4tn4J58v7vFUHg1UadeA3dvv8An58s+n1qaeHVfPtcXUGATu/de31p3JcY3+Jder7egzTDH/bWs/uGHMfOzr8tWd6DT4D9lkA3qPL2cjnrWbp0WonWtXxcwjmP/ln/ALP1q0ltqv2KISXcXmB1PEXbP1oTKqxjzK8l9nv29DRYqb2P9033G+bb05FVWK/YtSxCThn+UDluKJYNRN5GUuogmxs5j9x71TNvqZtdRAvIuXfb+66cfWhsyhCOnvLp37+hZsmU6VpR8huRHxj7vy9a0Vx9pceUQQo+fHB9qxbC31D+zNNzex4Cxk/uu2361fEGo/aGJvIzFt4Hlc5oWwVox5n7y69+/oOkI/s1j9mZf+meOTz1qK7bGv6ePKLfupvmHQcpUc9vqf8AZ7L9rjMvr5fvUNzBfnW7DF3Hjypc/uvdKTHTjG795fa79vQ1Im/f3X7o8Ef8C4pqSH7FAwt2JO0bOPl96rpBf+bc4vE5I25iHHFNW21MWsSi+jDDbuPk9qZHJH+ZdO/b0NDeftRXyTjbnzOMfSs/Tm3afdfuCuJ5Rt4+b5zzU32a+80n7au3A/5YiqFhbagLC6H21d5mk25iGPvml1HGMeV+8t138/I15mImth5ecsef7vymkiZvtNx+6wPl+bI+biqcttf+dbH7euAxz+5H9006K2vhcTk3ykHGP3I9KZPJG3xLbz7+hBq0rrpKk2xJMyjZuHHz1os8n2hP9Hz8p+fcOPasbU7TUf7NUG/Ut5q5/cj+/WgbXUPPQjUB5YU5HkjOaDSUYci95bvv5eRKJJDDc/6KVA3fxD5qY8k3lWh+ynO4fLvHy8Goja3/AJM+dQHO7b+5HFRyWeo7LUDUfmDDd+5HoaCVGHdf+TdippawfY9RzeyhftEnzeb0q/LHCZLMC9lxkkHzevymqOlSr9k1EGxnI8+Tjy15/Wr7yr5loBZTjkgZRePlPvQjarfnfz7djjNfjhPxV8Ln7VJkpdLxJ0Hkg10F+kQ8OH/TJMeanzebz/rRXPeKZlT4l+EWa1mUebcgHYvzEwdOtdFfyg+HSPsU2PNT5di/89R2zStuaQvzQ9Y9vM0JkhN/aYvJCcNgeb14pIY7fzrz/Tpfv8/vunyinTzAX9oBZTdG52Lxx9aIZV867/0Cbl+fkXn5R71Rz68vy8u5WSO3FhaD7fLjeuGM3J5qEJB/wlGPt02fsg/5bcfeNWElT7DaZ0+c4cYHlrxz9ah85P8AhKgPsUufsgP3F/vn3pM2jf3vR9iXy7cabdYvpSCJM5mzjrUtwkIurL/TJuS2D5vX5aY0q/2Zd4sZhgP1ReevvU9w6i5sv9DlPLY+QfL8v1pmbbv9/bsMdYPOu/8ATJOIhn970+9WbpYth4dsgb+ZQWXkTYP3q03lUz3i/Ypv9UvOxefve9ZelTIvhqwzYyt8yj7in+L60uppC/J849uzNPZB/amDey7vKHHm9eTVKOGA2GrD7bNjzJMnzv8AZFaQK/2r/wAej8w/e2jjk+9Uo3X7Bq3+iSf6yTjaOflHvQRCT/Lt3KWrRQC50IfbJiTPwfO5+7V+1jtv7Tu9uoTlgEyPO4FV9VdftWhYs3/13XaPl+X61ftX/wCJneA2MijC4baMEfnQtzScn7Nej7fzGakMB0C0Y3s+3Kc+b71flii/tm2H2ybcYZeBL7pVRJS3hy0P2OXO5Pl2jn5uvWtGVh/bFri3b/Uy/NgccpSRM2+Z/wDb3bsZGkRQNa6z/pkxX7RJn977VoNHCV07ddzD0Pm9flqrpD4h1oi0cYuJMDaPm4q+zhRp/wDorEHtx8vy0LYdaT9o/wDgfyhBFF/al2RcybvLjBHmf71ZOrJD/wAIfPm4kZcjrJzneK1oJX/te9AtXwEi+bjn71Z2qsw8Hzt9nIfj5eP74olswo3VSPrDsa1wkf2+2Bmk3YbAD0kCQ+belZ5TyN/z5x8vb0p11MYrqF5Igsaq7NIzABAB3NJZ3K3CXEsCJJGcFGRgyyDHUEVRy3fL8v1GusDW9lmaTy967G38k4OMmoUEf/CUSDzG8z7MPl3dt3pVovIILQi2BJcApn7vB5qshceJnHkjBth8+f8Aa6UmXC/vej6ruKEiTS7s+bJs8yXcd3Q7zUsqxCTTcyP9/wCT5uv7tv6UZkOm3P7kZ3yALnr8x5p1wziXTgIlPzn+L7v7tvagV3d/P8gXyxd3eJH3BBuG7pwazdF8g+FrYvK4iycNuwT+8NagaQ3FwPIX7g53/e6+1ZmiSTf8I1bkWwJyfk3dPnPtR1Ljf2fzj1XZmiyxDV4iZG8wwkKM8EZqNljNpqgVmOS+/J6fLU7tJ/aKAQgjyiS27pz06VCzym01DMSjBfA3fe+X6UGcb6fLr5lLVUh+y6NudwouItvzdfrWggX+3JTk7/s6cdsbmqlqbTfZtLPkKT9oi439P0q+hf8AtWXMY/1C87v9puOlIud/Z/f180VZRbjR78bm8r95k5Oc4qxcfZxLZ7iQ275OTzx3qKSSb+zL4+Qm4eZ8u/rx9KsTSTiS3H2dGyeT5n3ePpVEu/59V2M3SvIXXtb253Zi3df7tWT9k/s2HBbyQ64POc5qDTWmGt6wRCvWL+Pr8v0q0Zbj7HETaoG3r8vm+/0pI0q351/271X8pM/2f7ZGxH7zY2OD0yKpt9lNpqQb7u99/X0qa81AWl7bJcG3i87KRmScLvbj5QCOTUZkuBa3+LaMgM//AC168fSgzgnp8uq7kNp9kOlaUSOAI9vB67avqLT7UxA/e7Rnr0qpYzXK6VppW3jOUjBHm9Bt+lXhLc+aV+zJtx97zf06UJaBVvzP59V3KUqWP9mt8p8vv1znNR3gtP7d08uvzeVLjg/7FWpprtrNm+yxhv7vne/0qG5e6/texIt4z+7lz+96fc9qTLpt33/m6rsSwi08+6AUdRu4PpQFsfscOV/djbt4NPgkuvPuSbeMHIx+968fSnRyXQtoiLaMtgZXzen6UzN3vv26rsGLNbk8fvdvoelZlktiNPvPl+Xz5N3B/vmtfzLnzSPs8e3H3vN/pis+xkuvsNzm1jz50mB53X5z7UdSoN8r17dUWJ1sxNa5UZ3Hbwf7pojSy+0zkIN+Bk4PpUkkl15kOLaPG45Pm9OD7UqSXP2iYfZ02jGD5vXj6UyLu2/Tuu5kasLAaSpCfJ5y4GD/AH60HTT/ALTEDGN5U7eD0qtqsl2dMBa1jV/NX5RLn+P6VoNJd+emLaLbg5bzeR+lFjWTfIter+0vIqrBp5hudsfdt2Qaa8WnhLUCP5d4xwfQ1deS6CSYt4+Acfvev6VznjXxanhSw0y71K1ylzeRWoCS/dZ+B26UnoRGUm9//Jl2LulC9FpqJMkJP2iTHymtKUXRltCHhHPPynn5TWDpWn2Is9S/0q78sTvu/wBKk/xq/Lp1iZLLN1edfk/0uT+6fehXOisoc7/+R8vU5bxtHcf8J74OkMkIUX0gAwc5MNdLfi6Hh0/PDv8ANTnBx/rhXG+PLCyj8X+E5PtF0ZP7UWM5uX4DR8c54ro9Q0+xHhok3FyU85ety5/5ajtmp1sy6aheGvWPT18zoLhbr7daHfFtw2flPXFOhF15t388Odw2/KePlFUJ9NsxqFmPtF1uw23/AEp+mPrSQ6bYNLe/6Td/ew/+lSf3R71Wpz2hyrXp/L5+pMgvPsFn+8h3eYuTtPPNeZ2Oo3j/ALT+oWTXA8pNET93zt6hunrzXcf2bpn9nWG6e52+YoX/AEl/X614zpkFi/7VN+vmzGEweQp85slhChI3ZzjPapbehs6cXzNX6/Z/4J73suxpV3mSIsfMIO08DmrMwn+1WWWj6tu4PPy1hx6dpg0m9KyXBUGTOZn68+9WpbDThcWADzFWLbczOf4frTuyJQjd79fs+XqXytx9qvfnjwYl2jB4+9WVpsV23hWyRZYlfcvJXtuqRtM037Tfj97xEu796/8Ate9Z2m6XpjeFbJpBJ5ZZed7dd1J3uawUFHd7x+z5PzOnAm/tPJZNvkjIx7mqaCb7Bq2HTd5kuDjp8oqAaPpi6rjyn3mLP329T71WTStOGn6sdkhVZJM5duDtHvT1Moxp930+yu/qW9UEn2jQvnXiYbuOvymr1qbj+0rsM6FAEwAvTg1iajpunLPof7twWmG0bjz8tXYdF0ptRutsTGXC7xvbH86NRzVP2au3s+i/m9RqrP8A8I3ZgSoJNyfNt4xmr8wm/tm1+dAvky5G3rylc82j6T/wj1s3lyeXuTJ3N1zzVqbRtK/tm1Tyn5glON74PKe/1palyjTu9X9r7K7eo7SBdG11vEybxcSbTt6cVoLDcsmnEzLlcFvl6/LXP6Vpukraa0VtztWZxyWPatJ9N0t4dOZ4SAQMfe5+WhXsVWUOd2v/AOAr+X1NO3SX+17wmQbTHHgbf96srV0mPhC4BmG7I5C9vMFPttL0kavdgW2W8uM4IY/3qzdVstKPhCdhbKFBGDtOc7xQ9hUYx9rG194fZX+ZF8YpLi38Ca1LDPs/0KVMAddwC/1rK/Z5eeb4SaK8k2f9HVFGPu4GKX4x6bpP/CJyRtbhHleOJSoI+9Kg/wAay/gBp+mj4dvDNbiRoLmaFiyEnCsRxR1M1CPsd39y7+p6pIkohtB5/wA4cZbH3uDVdUf/AISRz5vH2YfLj/aqi+naI1pak2SbC6gfuznODUK6ZpP/AAkjqbKIj7MODHkdabFGELS1ez+yu/qa4jl/sy5HnfMXkwdvT5zUlwj+bp3708SHPHX921ZC6bo4066/0KIjfJnMX+2elPl07RhJp/8AoMQ+c7f3XX5G60C5I3er6/ZXb1NYJJ9quT5pwUGAB061l6EkzeF7cCch8t823/poaP7O0YX1yDYw52An91x36Vm6NpujHwxCz2MTAlufK+b/AFh70dTSMIez3e8fsrs/M6rY/wBsU+aeIyCMdeetVikgs9QzKTkvg46fLVM6do/9owr9ggz5R2/ueOv0qL+zdH+z6gRYQ9Xz+6/2e1PUxjCK6vp0Xf1LGpRy/Z9LxMeJ4snb1q6qv/a8n7w48hOMf7TVg6hp+jiDS9thAA08YH7nqPfiryaZpP8AbEiiwt8+Qp/1Ix95valqXKMeTd9ei7+pcaN/7OvVMxJPmfNjpxUtxFKZbbFwQFbkbR83FZLaXpDaXesNPg2DzP8Allz07VJcaboqyWwOnwctwBD7d+KepPLG+76/ZXb1JNMgmGt6wzTHaxj2/L/s1aEcps4R9pJO9fm2j16Vh6fZaQ2sarE1jAY4zGVUwjC5XnHHfFSDTtBFhEf7OgCeYv8Ayw5+9QrmtSEXJXv9n7K7ep5l+0xLcQX/AIEaCYgrqyNwBx0Gf1r2DyZfsmoA3J5Zudo4+UV4f+0Rp+mHUPDqW1jEnls077IQMgOg549zXrNtpmhSabeMumW4GCf9QP7o6cVOuooxjyLV/wDgK7+pqWkUh0rSv9JIwsZztHPy9K0PLl88/wCkHG37u0fnXO2mlaIdM0xjplsSRHz5Aznb34rQXTNFNyyjTbbdtyT5A/wqlexFWMLvV9fsrv6lp4pfsDD7Ux/2to9aZdJL/a9iv2gjMcv8I5+5VFtM0IWLFdMt9menkDPX6VHdaXow1mwX+zrbmOUgCAY/h9vrQ7hCML7v7X2V29TZiik+0XJ+0NyRxtHHFNWKQWkIF0R93DbRzVGLS9HNxdf8S224xn9wOePpSLpWjfYoGbTbbbhcfuBkfpT1ItC+76fZXb1NYRS+dn7ScY+5tH51m2Ucg067H2kk+fJ82Bx85p39n6R9r2f2db79u7d5A/wrP07T9JaxvD/Z8OBPIDmHn71LW5UIx5Xq+n2V5+ZuyxuJLbM5yGPYfN8ppIkf7XPm4Jxt+XA44qnNpuk+dbA6fbksx2/uRx8p9qItN0r7VcAWFvuAGT5I54+lPUztG2727Lv6jdWUnSh/pmB5q/Pgc/PV90YSxE3eOD8uB83vWHqOn6QNJVxp8IQyrgCEA/frTfTtL8+INYQFsHafJGAPypalyUVFavd9F5eZMqsY7g/bNwy2eB8teI/tS3jW/h3wwiXW8/2lHLjjnZzmvZV07S/JuCthAPvbv3I5/SvDv2lrCye00OK0s44ykU87BY8HaqUpXsVSjGU7K/3Lse1aS7C11E/ZGJ+0SfLlef1rQld/MsyLVsk88r8nyn3qnpUcq2upASgM08hU4+7V6VZPOsv3o4J3cfe+U1RnVa9o/n37HE/EdnGpeG3W2ZlTXLX5ht7gjFdDqTsPDZItmJ81Pkyv/PYe9c58WpXsdKh1SS4WO1sNTs7qUkcIit8zH86121G11DwiLiw1S2uYmlUrPEwZSPOFS3ua0rXh6x7m7cO39oWf+jtjD5OV44+tOtndpLzNqykPxkr83yj3rzbxj8R54vFMWj+CtPfxHqltGzXEcDgRwk8AO/TPtXMeHvjXfnXGi8U6JLoWlz3DWbX05+WG5VBlD7e9HMZqk3BPTbz7nsnmSfYLIiy5Mi5Usvy814JoVxL/AMNC/aTbjM2o3kIwR/AAvX/gNe6L5sulaZKl4pR5EbcAMMCeMV4A1r4gjvdP8V+GrL+17tNQvb0W6sF3RPPJzn6DNKT2OujFWnttLufQxkmOj3n+jKMeZxuGD19qnuHm+12H+jr1b+P7vy/SuW8C68fFPw/OrrJJA1wJd0T43RMCQVP4iuqnRvtVgPtB6tnp83y07nLJJSe3Xv2E3zm8vgYI8eUmDv6/e9qz9He4XwzZEW6Egj5d/wDtdelXwjfbL3/ST/ql44+X71cZq3jHQ/C/g+2k1bWo45htKwRsrSyHd91UHJpN2ZcUnG2m8e/ZncF5xqu0QoU8kZbf05PtVdGmFjqZMaE75MAP1+Ue1eV3njzx9f3bX3hrwVcNp6RBhHfSrFNMuT8yr/SruhfF7wtd6DfPq2rLo+ol5BJY3nyzRNgDbjHrRzEqnZLbp3PQNWeQXGiDykJM4yd3T5T7VpQPMb25UxIAAuG39f0rjLjxl4Zvv7BntvEmnSJ5oO4Tpz8p6+lacHirw+t/csfEunkEL8puEwOvvTTQppezXo+/8xf8y5Og2rCCPflMLv8Af6VdmM39q2uI4yfJlz859U9q5MeKdAGg2o/4SawyGT5vPTPX61cm8WeHRq1sT4m07Hkyf8vMeOqe9K6HJK7/AO3u/Yv6Z9oWDWMQxbjPIceYeePpVwPd+Xp5FvCTxn96fl+X/drl9F8TaJcDVYovEdi8slw4jCzpk8cYGeateKfEem+GNBtNS1PVGWCPaAsZDPKxHCqO5NNNWLqJOb2/HsdFC91/aVyPJh27EwfNP+1/s1kas91/wiM+YIu3AlJ/jH+zXleq/EH4iRTPqWmeDJ3sLgxxwwSuBOAc7WZR90Gt/wAIeN7Txb4DvImuja65aYS9sZCBJC3mDt3X3pNl0qaVSG28e5r/ABde8a00KBIYiZtUgXHmE5w4bH3faoPgp9rh0PX4PJiDQ6zdpgyEYO/p92rnxEjebxJ4LtVuG+fUTIcY4Cxsc/rXHWmseIPAHjLVbXWbAf8ACLarqzvDqUcqlonm5XevYE0dbmS5XSUVa9vPuexb7zybYmCAybhkeafQ/wCzUCNc/wBvv+6hx9nH/LQ/3v8Adp4hc2toPtj53D5xjng1Esbf8JC/+kt/x7j5eP71UyIqPvbbPv3JQ93/AGfOfJh3b5MDzDz8x/2adM935lhmGH/WHP70/wBxv9mq91NDa6Rdy3GoLFEpkJkdlAX5j3rzjxJ8TUu9VsdF+H4fxFrQJZjEwFvENhGXk6Z5zik2gjFSb0XXv2PTxJe/bLgLBAQEXH74+/8As1Q0KW7/AOEahZYYTJluPNIH+sP+zXlN5qHxb0G5Gq6hHYataAj7Vp2nqDMiHOCuepFS+GfjL4Rfw0kGo6vc6XfxOyzW1xCQ6HeT6YPWknrqbezjyWVt49+zPZGe6+3RjyYdpjOT5p4Of92ome6Ntf7ooRjdjEh5+X/drz5vjF4F+3xN/wAJQu0RkH92cfjxWpa/EPwfdWV28Xi7TWWQMVDXCKR8voeaq6MFC1tO3fudLqLXJt9N/dQ58+Mn96f/AImrqNN/akmY4wPJXkOf7ze1cVqXjvwm1vpoXxbpZKzxk4uUPHqeaux+PvCJ1Z2HivSSDCox9qjwfmb3pXQ5L3Nu/fujo5HujY3mIot3z4HmH0/3alnkvBJBiCDBb5v3x44/3a5NvHXhP+z7xV8W6WWbfg/akz0+tY3iv4jQy3umaV4EuLfX9cuWJWOCZTFEoHLyMOgp3QlG7tZde/Y7fTmuhrmrHyYcHyv+Wp/un/ZqZXvvsMP7i33714844xu/3a8O/wCEn+LGgXmv3GpaJp98lmkc9zJbyYBj5+VB3IGa9S8HeJNP8U+DrHVNO1LdFI67/mG6Jt3KN6EUJ9zapBcyen2e/Y4v4vzXNx4jmhEEDfZNGecjzCcZnTn7v+zXpemz3c2iyyeTCGZMgeaf7g/2a831XTpvE3xK8Y2Vpe4ZNGjskY42+YxL4P5rT/hn4o1GO+1vwb4xuLa116xiV4PKcbbiIp95c9SMDIqbi5VypadO/c9Ks5LsaVpeIockRg/vT02/7taINz53McPl44IkOc/981nWS50jSf37EERYbjn5a0lXFyT57E7fucfnVLYwrW5np379yFmuzbHMUPmZ/wCehxjP0qC6M/8AbVjtSPHlS5y5/wBj2oup4LbTXe4v1jQEgyO4GOema4PxL8WPBula7Zh9cW6liSRGisl84liVwDt4zwaG0OnH3tF/N37HosTTma4zHGCCNvznnj6URtci2i+SLfhc/Of8K888P/GLwRqt5cxf24LGdmwI79TAQQMcbuK7y2uLefTbdob5HQhCsiuDuzjH50XRDjbddu/YtFrj7QQI4vK29d5zn8qo6e901pdZSLcJ5AvznpuPtWgADctiU7tv3M/rWVpgjWwvR9pZh9okyc/d+Y0dRwtyvTt3NGZpvOtvkjwWO75z/dPtSxGb7TOGRNvGCGOen0ps5UTWpMuMMe/3vlNEUkZurg+eOi8buBxQRbTbp+pT1Q3LaVnbH5nmrn5jj749q0yZPMQBV2EHdzzn2rhfiB4z0Lwr4bV9S1DfK8gMMER3yzkPnCgV5/qvxl8UR6pbSweBL+LT0ja5kM0nzGDu2B0YelJyRs6Upxsl1f6HvDGXypchA3O3n8s14v8AGxLm81eG3McbmLRbuVvmOASuK9L8KeJNI8T6CdT0a/E9tOCx+bmM45BHYiuN1nTLbxB421K1jvjlNKFqGLZGZM9aHqtCsOuSd5Lby8jrNO1Gxa01LeszIZn3fu2zir0uo2O6x3RzYB/d/u24+U0ukG5EF+RFDv8AtD4G44P6VelNx5lr+7izn5vmPHynpxTKqyhzvT8fL0Mm5fSdRlv7a/tPtMUqqJI5oC6suOhBGK8v1f4ZfD19IluodKurV3lXcLeWaNT+8APyg7entXpmqeK9I0TVJrfWdV0uwkcK0a3FyI2fj0NZHinxZpGleHIv7R1PS7WSd0kiSa5C7180HIz1HepdrM0oNc8VZ2vHr/wB3h/SvC3hdrGz0DTPscOHJ2ROS3HVmPLH3OadrNn4b12w1ex1ax+02szfMrwFsHYPmHHBHY10c008l9p7wpA8TqzBw5PG3jHFFu1402oAxWw+cD755+RfamSpx5b67fzf3vQ+dNR8NeMfDXhyGLwl4ik1OxMirb2V5ZEvGCcYD+g616p4NstL8PPpGlGCWV7TSo4Xb7OTvcfebGO5zXWj7b/Z1hiK2JEqfxn1+lITe/8ACVj91bf8enXe398+1TY6faxtJLtL7X/APGdS8I63YP4ivPBuufYbG9nef7Bcab5io3fax+6D7Cp5NB8fXQ05LrxfBbs4IPkaIuY+OcEjk17Ju1D+y7vdFaD/AFmMO3Tn2qxO179qs/kts5bPzt/d+lPlIdZJ7d/teXoeD2fwu1H7bqsd5498RyQyqDJ5dpsZ+vGSTt4HbFdX4K8GeCdB8P2s8Hh/zr1mUyXVzbtNIzbuu5s4/wCA4Femg332u6/d22PLXHzt/te1UdGN8PDlpiO2LDHV2xjd9KFGz0D2sXG77x+15PyF+2ad/aQ/0GTd5QAP2Y8cn2rFm03wzdQ6pLc+H7WWVpJMvJp6sx4HcrXWKbz+0PmSDy/LGSHOep9qrA3f2XUcLAfnfHzH0+lVYwjOP5faOC1fwf4Ee60gnwpZKXmGdtgFDDb3wOasxeCPh+b24B8I2ZIC8fYeB9OK63VWuhPo2Y4M+eM/OePlPtV+I3v2yfMdvtwuDvbJ6+1Kxc5x5F6P7Xmebx+CfAX9hQOvhO0OWTLGy5PPPNWZfBPgD+1bdf8AhELPBikyPsHBOUxxj6/nXZg339kWwEdtkFP42x1+lWJmvP7VtsJb48mTq7eqe1Fgc43f/b32vI8qX4dfDu6i1c3HhVSRKwUxRSIUA6AbSMVa0f4d/D3SLvS7+z8My/aUIZWlE0oBx12uxGfwrvNKe+K6vlLUsLh8fO2On0q8jXhisTst8kAn52/u/ShIqpKKk9P/ACby9ChFd6b/AGnc/wCgyZ8uMf8AHqf9r2ryn4neA9G1/TE1vSBeaLrdscC4trYKso38+YABu+pNe0w/a/7QuCUg27Ex85z39qyNZ+2f8IjcgrBnHUMT/GPalJaDoTi6kV5x+0eZeBPCuraJ8QmufEN/d61pkUBFlJcWoDrI33zgD2/WvQfE+kaP4n0PV9Lv7OZYLhQpeODbIpA4ZTjgiulmN19tt/kg24bPzHPT6UK115t1tWDII25c+nfimo20MJ1VKzt07+Z4Y3w61/T4LR9I8c60FLhRHdaekwRccdepFJL8M7y414W91418TSRtb5naOFUZ8nouB8or3KN737NBlLffkZ+c4/lUC/af+Ejc7Ytv2YfxHP3vpS5EbRxHxej6nk1l8IPBMVvNcX9rrupeU74ivbiRkJDcHAxk/WvQLKz0LSU0yLStBjtIt5O2CzVP+WbdcDmt9jcnT7jKwht0mPmOMbj7UsxufN0/iL/WfN8x/wCebe1Oxk6qbb9evkZ0VxYG/uv+JdJ9xSf9HHPWsTS7fRn8ORvLoaSszMSTaKx/1h74rr4zcfbrj5YsbF2/MffrxWdoy3Q8OxoghEgZ/wCI4/1h9qLO5aqLk+cevkylJaaG9/CraBEd0bdbJOn5Vj/8Ix4PePUv+KM07cC3zf2ZF/d7ccV3DC4N7CQItgQ7uTnPtxURM5t9Q3CPq23k/wB3vTszKNSOmnbr5nB6l4V8HLaaXt8G6cu6ePONNiBPqDxzWhH4T8HDV3UeDdLH7hSB/ZkWB8zdttdFqf2j7NpefK3faIt2CcVfTf8A2rJ93Z5K8Z5zuakVOceTbv180cOfCfg86Vet/wAIZpowZMf8S2LI49ccVrWOk+HdImhfS/DNrZySEAvb2KRnp3IAzW4fO/s6+yY/M/ebeuOnercvm7oNuzG75859O1MiVRX279fI5yxubU61q27TpTjywf3AP8JrybxH8JNI1C5vNR0yfXtKhvWBmsrPEcLvn72O34V7ZY+cNd1X/VlSIivJz0PWi4+3DTUw0HneYuDzj71Jq6N/apTWn8vXyPO/g/4YbwPoFtp2pWdxe6lK0k1xcGMNliQAMnnAUCn/ABC8F6R40sZZZbG/sNTspy8N/aRqkygAZXd3B969LcXP2yH54guxtwweeR0qALcfZdRAePJZ9pweOO9FiFWi2nbt1fc8Ls/h94u01NNl0HxprKW0pTKXtpHceX8vBXdx+gqa98P/ABdlvYJV8RW/2m1K7QlgiJOueTJjv7DivbNPW4/snS90ke7bHu+Xtt7Vo4l88ncvlbeBjnNJRCriUpNcqe/V9zw+w+HF1rOy/wDiTeXviEW6sIbBbZLeCJ2PLYQgsfQmu+sNH0TQdS02DR/DMVpGIpMeTbIp/g5J6k+5NdZKk/2OQeYhlzw23jrVa6Wb+27DbIu3y5dwK9fuUWsKNZSk3b+bq+xi6vomia+LyHWPDcN4hAGZrdGYfL2PUH3FeZv8EtAWyhfTbnxbpw+QtFb3gCkg8Ngg9M17jCsonudzrgkbfl6cUxFuPskX75A2Fydn0qrXM41lF6eXV9jxyT4aaxbagk2jeMPF8F1GAVkunjuExnoUOAfxqhF4B8WalDcSaj421/yo53BjtLaK33/NySV/wr3fZP55bzV8vbjbs5z9c1Qs1uPsd1mVN3nSY+Tp8xqeVGkcQnHZdO55VcfCt3Nuknijx46OSGBv06bT/s8VHa/CRImntoPEnjpIAoAX7enQjoTivZpEm8yD96oAb5vl68GlRZfPmO9QvGPl9qfKiPrOmy28+55H4b+G+heEI31G2stW1C+dkRZdQlWYxDfzs6bc969PkvJDPEG0u4JII3fLgD060mpJcDSyGkTf5i87P9sVfdJ/NQrKoQA7hs6n86drDnVjKKulu+r8jx2++Gt9Ya1qmq+BdS1Hw0b0N9pto7eKeKZuTkK5wvXtWp8JNI8Q6FpE114utpbzXL26zJKoQfu1BCcDAHFemqlwFfdOpJzt+TGP1prpc4hAnTdu+Y7OvHbmlYj26as0vxMzS1X7PqAW8OTO/wA24cVekC77XN3gg/3h83yms7Szbta6j/oh2id8jyutXZRbiS0BtCeeP3XT5TVIqqvff/A7HgP7TFrbzeMvAzSMjl9RWNi204X5ePpUv7SFlaSP8Pg0iSbtZ8kk7T8hccfT9Kh/aVkjfxf4QW3sbqX7JepcXBhtmYLH8vXA9ulM/aD1OymXwM9nZXDx2+pC9mKWjYEO8deP0qO5rZuKt5fke+3AiXULALebVAcBQy9NtR24Qy6l/wATEnL8YdePkFRtNZXF5pssdk+2RGdSbfHBX6UWhtDPqX/EvYfvO9v1+Qe1MlJqPXbsv5iIRJ/Z1h/xM3GJE/jXnmnBEHisH7cx/wBE6F1/vGmBrP8AsuwJsGI8xMD7P05+lKGtj4rUCyYf6J1MGP4j7UGuvvb7S6ImEaf2Tej+0HOTJzvXjrVqdENxZYvX4Lc715+WqmbX+yLwiyIH7zjyev6VamNuLmxxaEZLYHldPlpmMr3+/t2FVUN5d/6a3+rXjevH3qz9JVB4btcXzgZHO9f73Sry/Z/tl5i0IxEuf3XX71UNI+zjw1af6GcEj5RFn+KjqUvg+ce3ZmptT+0+bt8+V93cOeTVdIwbLU8XTn55Odw44FWT5P8AaQBtiT5XDeX05qshiFhqhEBxvkyoTr8opmUb/l27kOqRr52ik3bcTjALD5vlNaESoL2cm8Y/Kvy7hx1rP1QRebon+j9Z1x8n3flNaEYtzezr9l+YKuW8vr1o6lTfuL0fb+YoCNTotsBfMcMnzb19aszKh1e2/wBMYEQy8bl9UqsnkLotsRZnG5Pl8r3qzKIP7Yth9m58mXnyvdKQ38T/AO3u3YoaUibNYU3zDNw/zb144q6yI0em4vGGMfxD5vlqlpX2fZrLfYzxcP8AL5XXirgEIh00m1PO3pH935aFsXVvzv8A4H8pPCE/tO5/0pi2xPl3Dj71ZOrIn/CJXG66cr67h/fFa0JhOqXS/ZiCI0y/l9evFZGsmP8A4Q65ItTn+7s/2xzSlsKhf2kPWPY2p1X7dbf6Q2cNhcjnimRiP7Rf/wClNyV3fMPl+WlnMf8AaFn+4PIfnZ04psXl/atQ/wBGPBXnYPm+WqOdfD8vLuRlY/sVmFvH2+YuG3DnrxTVCf8ACTN+/bf9m+7kf3qkV1FlaEWbHLL8uwcdeajVgfFJXyD/AMe338D+9SZor+96PsTbUGnXX+kMV3yZbI+X5jxUkqr5un5mYnedvI+b921MDD7BdYgPDycYHzfMeafO2JdN/ddXPYfJ+7agz1u/n+Q6JVF9ckSsTsXIz0rM0d4x4aib7QVUO/z56/vGrUjP+nXP7o/cXnA+brWXobAeFom8jf8AM/yYH/PRqOpcfg+cfyZpOV/tODM5BMbYTP3veoQqeTqWJixJbcCfu/LVpm/06EGA8oTv4+X2qEn/AEfUT5OMFv8Agfy0zOL2+X5lDVhGbTSMXDbRcRYIb71XwE/tuXLtv+zp8ue25uapatIVs9KIt2/4+Ivl44q6jt/bUg8o/wDHunzcf3m4qTWV/Z/f27or/uV0m/xM2zMgLE9OKuzFPMtf3hzu+UZ+9xVRmb+ytQJgIP7z5OOeKvSyFfI/clixx2+XimjOe/zfbsjPsJIv7c1YCUl8Rbh6fKabMtrJpkYNzJ5fmL8249d1GmyE67q48hgQIucjn5TUwlZdPiItH++PkyP71CNJaTVv7vVdh8gt/t8JaVw4RsDceeRUHmWxt9Q/et9593zHjirrSSfbY/8AR2I2N82RxyPeqxmkFtf4tm4Z/wCJeeOvWhkRvZfLqu5HYvbnStMzIQMR45PJ21eBg+2Nh283ZyuTjFUrOaQaVpeLdjlYx1HHy9etXzJJ5x/0dsbfvZH5daFsKr8T+fVdyrI1q1lIBMxj3ctubg5qC9e3GuacXkYHy5cfMefuVdkkk+ysRasDn7uV9frVa6kl/tqxxbsR5cueV4+570MdPf8A8C6rsSxPb+fdHzG6jdyeOKjEtn/Z8O6VggCYO5varEMspnuM27DBGDuXnj601JZfsUR+zHOF+Xcvt70yf+B1XYcHtftRYSN5u3pubpWdYNaCzvcTNt8+TcdzcfNWr50vmlfsz4xnduX8utUdPllNtdf6K2fPk+XcvPzfWkVD4X8uqLDyWxa3/eN975OTz8ppEa2+0zfvG3cZG5uOKklll82D/R25Y5O4cfKfeljll8+UG3bbxg7hzx9aZn0+XddzJ1T7GdH4lfb5q4O5v+elaTvaGeEmR9+DtG5ueKq6pLIdKYm2YHzF43L/AHx71feWXzYgLdiDnJ3Djj60dTWT91er6rsiNRakTAO/zZ3fM1Ru1pstx5j7Q2F+ZueKsmWXY+bdsjOBuHP61GZpiISbVwS3I3LxwfegyTf9NGNpi6yYb4IdPDGd8ZD9atyf22Hth/xLs554f0NM0xIPJv8A/TGCmd8t5g4q3KIQ9sDesOeP3i88Gix1VJ++9F93kVYl1k3dz/yDcfL1D+lZWpjWT4eO8aaR5qcAP/z1Fb0Ih+13RF6wY7cjzBxx1rG1Rbf/AIRsg6g2BKnPmr/z2FS1ozShP95HRbx6Fy4Gt/2hZ5Om/wAfZ/T60lv/AG6Zb75tNzv/ALr/ANxcd6muBB/aVkRfsSA/Hmr/AHaS2EHnaj/p7n5xn96OPkFFiOb3dlt2/vFBF106fYfvdOH7xc/I/PP1p7DWP+EnT95YA/Zem1v731qWMWv9macDfMFEi7T5g55p+YB4tT/SSXNpwN4/vGixrzu8vdW0ugwJrI0263zWP/LTGEbpzU08esm4sv39luDNn5G5+X60Frb+yL7bduVzIGO/oasz+R9o08GZjydh3dflosYubv8ACuvTyKix6z9uu/39ljy0x+7b/a96p6RHq58PWpjntByDyh6bq10aEX97++bPlJu+bp96qGkC3/4Re1zMwjyMNk9d1FlcpVHyfCt49PJl3Zqf2/Pm2m3yxkbGz1+tVI01P7HqQ861yXkx8h44Fah8saquXbzPK4XJ5GaqoY1sdWIc48yTcc9DtFBlGb7Lp08ylqcWpFtIbzrUbZ13fKeTtNXoRqn2yYNJabcL0Rs96j1PyidGJkYEXC7Bn73ymtBDEL6bDnzNq7lz064phOo+RaLZ9PMyPL1X+x4FEtp5mU52N0zU0qan/a1qfNtAPJkz8h9U96WM240OEiZvJ3L85JzndVucp/bNoC5DeTIQM8HlKVhub5novtdPIydOh1MHVQk1qCZ2Iyh9Ksxx6qbay23FqGwMnyzyMVDppgZNaBmfHnvuOTxxVuAW5tNMPmuQgXYeeflprYurJqT0/DyCOLU/t8x+0223YnHlnOeax9Yi1X/hFrjNzb9P+eZ6bxXRQyRHUrgAt5hjTI56c1jawYF8I3Q3NsHU/N13ilJaBQm/aR0W8eiLk8Wq/bLbF1bAYbP7s+lJFDqpnvf9Lt8krt/ddPlq5cPEb+0JLbsNgYPPFIhtxNfZZ+SN/wB7j5aLGSqS5fhW3ZdyiIdXFnbAXluH3KCfK7VEItT/AOEiIF5Bt+z5I8r/AGqtn7GLK1BZzGHXafm5NRn7OfEpyX3i26fN/eoaNYzfve70f2UCwamLG4zew53vj910G40s8Gpmaw/02LHmHP7of3GqVWtRYXIBfbvfd97+8aLhrbztP5f752/e6eW1OxHPK707/ZXYakGo/bJx9ujxsXH7oVmaPBqX/CNx7L2IPuf/AJZDH+sNbELWpvrjBfdsXPDdKytGNmvhqMSNIE3Pz8//AD0al1NIylybdY/ZXZmi8Gp/bIAL6PZsbcDEOT7VALfUjFf7r+Pb82AIh/d71aka1+2253PnY2B8/Soh9j8i/wBhkyd277/92nYzjJ22/wDJV3KWo22o/Z9N330Zb7RFnEQ/Sri2+of2vJ/pybfIX/lkM/eaq2p/Y/sul5Mm0Txbfv8ANX1Nv/az/f3eQuPvdNzUFynLk27/AGV3RBFFfLYXpnvFcjzOkYx04qWe21Hdb41BfvfNmFeeO1Ru1r/Zd+QXKfvM/e9Ksym0LW+S+d3yff8ASnYzcne9u/2V2MvT7bUf7c1T/iYJjEWMQj0PWrJtNVNmo/tJPN3jnyFx1ptj9l/tzVMF9xEWR83oasgWAtFwZPL3gZy/XNJI0qVJcy06R+yuwNaah9qjI1L5QpyPIXPaqrWeom2v86mOS+P3C+ner7/ZRdJnzN+04+/7VWk+yC2vQ3mfebP3/SixnCctNO32V3Ktlaah/ZemY1LHyx5HkL029K0Daah53/IUITb93yFzmqdk1mNK0zPmYxHj7/XbWgv2Q3JI3+Zt5+/0oS0HVnLmenf7K7laW11I2zH+1AG9fIXHWq9zZ6h/a9jjVD9yXJ8heny1cc2P2WT/AFnl5Ofv+tVrl7MazYD95kpLj7/+zQ0OnKV9u/2V2JYrTUfPnB1Q4yMfuE9KatpqIsov+Jqc4XP7hPapYfsYubr/AFmSRu+/6Ui/YhYQ58zZ8uPv+1FieeV9u32V2FNnqPn5GqkJt+75CZzVKwtNR+z3ZGqnPnvj9wnrWp/opuOkm/b/ALfSqditn9nu22vt85933+eadgjUlyvTt9lD5bPUPMg/4mh4bn9wn9009LS/82TOpHHGP3KelSubZJLf7+d3y/e/umlT7OLib7+7A3fe6YosRzytt0/lXcy9Ts9R/sw/8TQ5Ei5/cpz84q+9pf8AnREamwABBHkpzVPURbJoxwshXzFwPn/56Vpv9nNxDkOXwdv3umKLFynLlWnV/ZXkQra3wWTOpEnnH7leKa9rfbYR/aZzuGT5K88GpwLULPtDgc7+G9KaVtfKtsK+zcNn3uOKLGanLt/5KirpDo0WoZtmAFw/y7fvVbmZA9r/AKMxyf7n3eDVXSFuDFqA8yPzDcPtO3gdPer0izb7cCSPIPzZXrwenNMdVr2j/wCD2IoWT7bdD7O3G35tnXjpWLqrxjwuxFo/+uX5dn/TYVtwrcfbro74tny4G05zj61j6mLoeF2/exbxKnOz/psPepexrQt7SPrHuX7mRf7SscWj9H52Dj5elLbSDztQP2NuHGPlHzfIKdcrc/2hY/vYsfPn5OT8v1otI7vztQ3zoSXGz5OnyCgi65fl5/zFRXxplhmyYnzE4wPl+agO58Wp/oxA+yfe44+Y1LHDc/2bZA3SqwdcnYOeajMVz/wliEzgp9kx9wf3qGapr3ttpdyUM39l3pFoRzJ8vHNWLh3FzYf6MSSW7j5flqARzjTL4m6DElyp2j5frU88cv2iy/0jnLZO0c/LRcxdr9OvfsCPJ9uvP9Hx+7TByPm+9WfpEkv/AAjFqfs2Tx8uR/e61oJHIb67H2k58tMfKvH3vas/S45v+Eatv9Kw3rtXH3qXUtW5em8e/ZmqWcamAISV8r7+Rxz0qsGYWWp/uejycZHPy1Y8uT+0gfPbaIvu4HPNVQr/AGLVMzn78mOBx8tBlG35d+5FqzN5mifuc5uF5yPl+U1oxyOb+YeRgBV+fI+brWbqqyZ0bE5x9pTPA5+U1fiST+0Zz5527FwuBkdaEVNL2a9H37lISSDRIWa1JbcvyZH96rsjv/aduPJyPKkOcjjlKqiOZdHhU3I37l+faMfeqxKj/wBq2379seTJxgc8p7Uwla72+137FHSmk3awBbnJnb+IfNxVqGWYWmn4tichQfmHy/LVbS4pc6uPtPzGdsHA+XjvU0UU5s9PK3ZHCbvlXn5fpSRdSzk9unfsWY5Zvt8y/Zjt2L824c9aytZeU+FbnNv26bh/fFakUcv9oTD7UxGxPl2r789KytYjdfCtzuumYY64UD749qJbBQt7SO28e5r3Ekv2y2xASMNk7hxxRA8purvMGACuPmHzfLROkn222xOwHzcYHPH0oiRzc3YE7Dlew+X5aZhpy9NvPuIHmFrFi1JO4fLvHHNVTJMPEfFtlfs33tw/vVZMcptYcXjA7hl9q88/Sq4SX/hISv2nj7PnG1c/e+lNmkLe9ts+5Kjz/YZ/9G53yYG8c/MaWaWYS2ObbkyH+McfI1J5cv2G4xdnO58Havy/Mfaknil87T/9KY/vDn5V5/dt7UugtLvbr37EqSTfbpx9n+XYuDuHPWsnSXnbwygS23He/G4f89WrSSOX+0LgfbGHyL8u1eOvtWTo0cv/AAjEZW+KfO/O1cf61vajqawS5Om8e/Zm28k/2uD/AEbja2TuHFRtJL9nvswYxuI+Yc/LRIHF9br9sblG+XC/N79KiKMIb8/bSc7uML8vy/SnoYpLTb8e5Bqks/2bTD9n5+0RZG8VeV5P7Uk/cnHkrzuH95qztUVza6Xi+PNxF82F5/Sr8auuqyBrkn9wvBCg/ebnpSNJpezW3Xv3RG0kx06+zb8/vONw54q1JJPmDFvxu+b5xxxVMhzpl/8A6USR5nzYXjj6VbnV824+0kHd6L83H0pmckr9OvfsUbB5hrmqZtyBiLB3D0NXlkuBAP8ARcMG+7vHrVOwjca5qf8ApRY7YvlwvHDe1W9r/Z/mvTncPnwvr06UDq25lttHv2Q95ZxcIBb5TacneOOlVzJP9mvM256tj5xyMVOyOLmPN0QNp+XC89Paop4pBbXZ+1MMhiOF+Xj6UERtpt+Pcr2kkx0zTP8AR+cR5+ccfLV8yz/aNv2f5Nv3t4rOtFcaTpebsjiPJwvPy9OlX8H7Vxd87PuYXPXr0oVrF1UuZ7de/cb5s5tnJtsNuPG8etVrqSb+2bDFvkbJed44+7UmMWsoN+D8x+f5eOagvP8AkM6eTebfkl4+Xn7tJ2HTS5nt179i/G8vnT/uOMjB3Dnio0eU2MP7n5sJxuHHSkjYCe4zeDqOMr8vFMVlOnw4vVXhPnyvPSndGfL5du/YuF5fNwIspjruHWqFhJOba8LQYYTvtG4c81bDp5+ftg6fcyv51Rs3QW15vvF/1z/Nlfl5ouhwj7r07dzQd5fMh/dcbjn5hxwaVGfz5QY/lGMHPXio5ZYxJBm5QDcerD5vlNJHPF9on/0lM8cbhxxRdEcrtt08+5V1J5jpLHyxv8xcjd28wVoMZDLFhBs53EnkVk6hJENGKm9TiRfm3Lz+8rReeDzoibtBwfl3r81K5pKL5dur7+RPmTbJ8gyM7eetRlptsH7td5YbxngDHao/Pg2zD7ZGc5/jX5eKYJ7cQ26i9jOCPmMi/NxRoZqD7fmY2k2Onm11M5lMYnfcdzcVeuLGw/0EMZQCfkw7c/LTtJeXytQPkDcLh8Lu+90q3K82+0xbqcnn5/u/KaDpq1Z+0er+/wAjOh0/T/t90v7/AHgLkbn6YrG1Ww03/hGHbdNt81Ru3N/z1Ga6mGSf7bdD7ONo24bf1OOlZN+058Mtm3UN5q/Lv6/vhUtaG1CtNVI+8949Rk+maWmp2GBNnD4G5+Rtp9pZ6YZdQAE5AbDDL8DaK0LmWf8AtOxH2Ychznf0OOnSkt5LoXGoH7Kv3xj951+RfanoQ6s3HWT2/mX8xkJp+lrptiTHNgyLgkvzzSSafph8UxoYpc/ZSdv7z+91rRjkuv7Nsv8ARUJ8xcjzOnP0ppkuf+ErXNsuPsnXzP8Aa+lJo0VWpeXvPaX2igNO0n+y74iGUgM+f9ZVmXT9J8+xxby7STjiT+7VsS3X9nXmbVM5kwPM6/pU88t19ps8WyZy2f3nTj6U7Ih1ql/ifX7XkZiabpIvrv8A0eXiNc8Sf7VUdNsdJbw1bsbeRhkc4k67q6JJLn7Zcn7MmdiY/edfve1Z+lS3Q8N2+y2QsRjHmY/i+lFlcqNapy/E94/a8mOax0r+0ADbvu8vj5ZPWqo0/S/sOpn7O+A8mch/7tbRkuftwxbLjy+T5nTn6VV825+xalm2QHdJj95/s/SixnCrU/mfT7XmZeo2Gm50bZA4zcLjh/7prQisdLGoz7YH8zYu7h/ek1KS5xpH+jrzcJu/edPlNXopLk38wa3QKEXB8zr19qaWo51J8i957P7XmYn2DSRo6bYJCm8ZJEmfvValstLXVbYeQ+4xSY+V/VKnE12dJjJtkLbhx5nH3vpVmWSf+1Lb9wuPKkyd/TlPaiwSqzu7yf2vteRhaTYaS8mrBreRlFw2eJOmOlWorDSRY2O+1fBC4+WTjip9GlufO1Um2QYuGx+868D2qzHJcG0sStsh4TOZMY+X6UJKxVWrU537z6fa8ipDp2ktfTBbV94RckrJ05rL1fTtKHhe6aO2cDHPD/3hXTpJcfapc26hdq4PmfX2rM1l5v8AhGLkvCobHTfn+IUmlYVGtU9pH3nvH7QsumaULy3T7M24hscP6UR6XpQnus2zdRnh/StKZpftlv8AuhjDfxe1JFLP59yPJXgjHz9ePpVWRj7apb4nt/N5maNO0c2kRNq+wkYGJOuarHTdKHiLYbZt32fPR/WtoSTm1iYW6bty5Xf05qvvnHiDAhXabfk7+fvUNFwrVPe957P7RTOnaT9jnP2VsBnz8sn940XGn6X5un4tnwZDj5ZOmxq1S8xs5SIl3ZfALcdTTZnn8yy/crnec/P0+RqVkSq07v3n1+15GamnaT9uuAbV9wRSflfpzWZotlpbeF42ktWILPxtf/nocV00TTfb5/3S7di4O/61maI8/wDwja7YVJ3Scb/+mjUrK5tGtPk+J7x+15Me9hpY1C2AtW3bG2na/Apq6fpnkX+y16bs/K3Py1pymf7dbnyk2bWz83INNLTGG9zEgxu24br8veqsYKrOy95/f5mLqdjpq2umEWhAM8QA2tkCtBdPsW1R82/PkryQ395qTVTP9m03Eab/ALRFuG7gVfUv/acg2jHkrznvuapsVOrPkXvPr180ZLWOnDTL8i2IUeZkYb0q1cWGn7rTdbE5b5DhuOKlcynTr75F3/vMDPtVmcy7rfCL9/5uenFUTKrO/wAT69fIxrCxsDrupqIDuCxZOG9Gq0+n6WLXm1Plbh8uG65p9g0h13VAyKFCxYOeTw1Wy1z9mBEUfm7vu7uMZo0HVqz517z2j18kVnsNPa4jVrYlsHBw2B0qA2Vh9nvcW5GCwbhueK1SZPPTCLs2nJzzmoJPNFvd5Rf4tuD1GO9BlGrP+Z/f5mXaWNgdK00/ZsqRHxhuu2ro0+wF3gWuH2Z3YPTNFp5h0vTPlXdiPcM9Plq7mT7Vgqvl7eDnnOaSLqVZ3fvPr18zNNhpptJCbL5NxypQ8nNV76wsF1nTQ1qDlJcYUnH3a2AZzbvlY/NycDPHWoLnf/a9jhV27JNxJ5H3elDCnWnzP3n16+RBFYWHn3P+iDIIydp54pqWGnnToD9kXYdmF2njpWjH5nn3GQuzjb69O9NjEosodoXfhcjt2zTI9rP+Z9OvkQnT7L7SP9ETft+/t4+lUbG1sza3260BQTyAgr157VtfP5v8Pl4/HNUdO84QXZYR7/Pk24zjr3pDhUlyvXt1Feys99tm1XJb5cr935T1ojs7M3U+LVN3y5YqMHirb790P3fvfN+R6UIH86XO3bxj16UGftJW36d/Mw9StbNNFObJSvmqAoQcfvK0ntLUzw5skLAHDbB8o9Kh1ITnSm2+UG8xcgg4/wBYKvN9o86PBj8vndwc5oNpVJcu/V9X5FZba0xORYgdd37sfN9KY1rZtFb/AOgLtLDC+WPl471cH2n95kw9fkwD+vNNIuCsWWiD5+bg46duaDNTff8AFmfpUcixaj/pEhPnvg4HHH0q28cjfY8XEgIPPA+b5fpRRVJFVJPnb/rYIYZPtdyftEm07cDA44+lZGrwTJ4acC6k3CROcD/nqPaiioezLoTftY+sTQuLeX+0bH/S5cYcEYXnj6U63t5vOvh9rl5cYOF4+Qe1FFCM+d8vy7L+YrJbzDTrMfbJs+YuThefm+lRNBL/AMJYg+1S4+yZ6L/e+lFFN9DaM3eXpLoiwbeVdMvAbuYnMhzhf8KsTW0v2i0/0qbIJycLzx9KKKDJ1Hf7+i7Cpby/bbk/apeY0xwvH3vas3SLeVvDNti6lBxnOB/e+lFFLqXGb5H6x6eTNMwy/bxi5lx5fIwvPP0qqYZPsGpA3MnLSc4Xj5fpRRTZEJvT5fmQ6nBJnRv9Jl4uEzwOflPtV9LeT+0Jm+1S4KLxheOvtRRQipzfIvR/mU4reVtFiBupclgd2Bn730q1NDJ/a9qftEuBDLxgc8p7UUUClN8z/wC3vyK2kQP5uqj7RLlp2weOOB7VatreR7Gy/wBJlBVVJIA54+lFFCFWm+Z/L8idY3+1ynz5MbVwMDjr7Vla3C//AAjV0pnkJI68cfMPaiiiWw6En7SPrE05o3+2W3758fN6c8fSkihb7RdnzpPmK46cfL9KKKZlzPl+X6iLA4s4l8+XIK/Nxk8/SoDC/wDwkIfz5MfZ8beMdfpRRQVGbvL5k4hb7JOvnyfMznPHHJ6cUlxG4m0/98/Ehz05/dt7UUUhKTu/n+QsUTf2lct50mCijHGB+lZejwsfCyoJpAQ8nzDGf9a1FFLqbRk+T5x/JmtJE3262bzX+VW44waYIysWoHzHO4see3y9qKKoxUnp/XUr6kha100F2yJ4ue5q4q/8TSRsn/UqMdvvNRRSLk/c+/8ANEMiEadfje2T5hz6cVZnXL253MMP+fFFFMzb1+/8inYpt13U23MdyxcHoOGq75JNv5fmSA5+8Dz1oopDrSfMvSP5IlZcyK2TwDx+VV5UxbXeGb5gx+nHaiigzi9StZxn+ytNXe3AjOe5+WruzF3v3NymMdutFFC2LqN8z+ZG8GbWSPzJPmJO7PI5qvdRk6vpx3thEl4z977vWiihjpyfN8n+RZjj/f3JLP8AMR36cdqasI+wwpvf5QnIbk9KKKaJ5nf7icxjzQ25umMZ4rP0+BRbXi7nw0787uRz2oopLccJPlfyLskQLwnc/wAp/vHng9aSKIC5mO5+dvG4+lFFBHM7f13M/VLZW0hl3yDEinIc5/1grQeBTNE26T5QRjccHiiin1NZSfKter/QcYFw/wA0nzf7Z4qJrVDHAu+XCHP3zk8d6KKDJTl3P//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6262=[""].join("\n");
var outline_f6_7_6262=null;
var title_f6_7_6263="Dextroamphetamine: Pediatric drug information";
var content_f6_7_6263=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dextroamphetamine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"    see \"Dextroamphetamine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/15/28917?source=see_link\">",
"    see \"Dextroamphetamine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dexedrine&reg; Spansule&reg;;",
"     </li>",
"     <li>",
"      ProCentra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dexedrine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Amphetamine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anorexiant",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Central Nervous System Stimulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=see_link\">",
"      see \"Dextroamphetamine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Attention-deficit/hyperactivity disorder:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release tablets; oral solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 3-5 years: Oral: Initial: 2.5 mg once daily in the  morning; increase by 2.5 mg increments at weekly intervals until optimal response is obtained; maximum daily dose:  40 mg/",
"     <b>",
"      day",
"     </b>",
"     in 2-3 divided doses; use intervals of 4-6 hours between doses.",
"     <b>",
"      Note:",
"     </b>",
"     Although FDA approved, current guidelines do not recommend use in children &le;5 years due to insufficient evidence (AAP, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children &ge;6 years and Adolescents: Oral: Initial: 5 mg once or twice daily with first dose in the morning; increase by 5 mg increments at weekly intervals until optimal response is obtained, usual range 5-20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"     in 2-3 divided doses; use intervals of 4-6 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended/sustained release capsules: Children &ge;6 years and Adolescents: Oral: Initial: 5 mg once or twice daily with first dose in the morning; increase by 5 mg increments  at weekly intervals until optimal response is obtained, usual range: 5-20 mg/",
"     <b>",
"      day",
"     </b>",
"     ; maximum daily dose: 40 mg/",
"     <b>",
"      day",
"     </b>",
"     in 1-2 divided doses; use intervals of 6-8 hours between doses; in patients &gt;50 kg, a maximum daily dose of 60 mg/",
"     <b>",
"      da",
"     </b>",
"     y in divided doses has been used (Dopheide, 2009; Pliszka, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release tablets, oral solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 6-12 years: Oral: Initial: 5 mg daily, may increase at 5 mg increments at weekly intervals until optimal response is obtained; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     in 1-3 divided doses: use intervals of 4-6 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: Oral: Initial: 10 mg daily, may increase at 10 mg increments at weekly intervals until optimal response is obtained; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     in 1-3 divided doses; use intervals of 4-6 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended/sustained release capsules:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Children 6-12 years: Oral: Initial: 5 mg daily, may increase at 5 mg increments at weekly intervals until optimal response is obtained; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     in 1-2 divided doses; use intervals of 6-8 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: Oral: Initial: 10 mg daily, may increase at 10 mg increments at weekly intervals until optimal response is obtained; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"     in 1-2 divided doses; use intervals of 6-8 hours between doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Obesity secondary to hypothalamic-pituitary dysfunction:",
"     </b>",
"     Limited data available: Children &ge;6 years and Adolescents: Immediate release tablet; oral solution: Oral: Initial: 5 mg/day, may increase at 2.5 mg increments at weekly intervals until optimal response is obtained; additional daily doses may be given before lunch and dinner if necessary; dosing based on a small, open-label trial of five children (age: 6-9 years) postsurgical resection for management of craniopharyngioma (Mason, 2002); further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Extended/sustained release capsules; immediate release tablets; oral solution: Oral: Initial: 10 mg daily, may increase at 10 mg increments in weekly intervals until side effects appear; maximum daily dose: 60 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as sulfate: 5 mg, 10 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sustained release, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dexedrine&reg; Spansule&reg;: 5 mg, 10 mg, 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ProCentra&reg;: 5 mg/5 mL (480 mL) [contains benzoic acid; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule (sustained release), oral solution",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F158813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-II",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Dexedrine&reg; Spansule&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088583.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088583.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     ProCentra&reg;:  file://fsclabs.com/pdf/2010_Updates/2639_ProCentraMedGuide.pdf",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer initial dose upon awakening; do not administer doses late in the evening due to potential for insomnia. Do not crush or chew extended/sustained release preparations.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F4469949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light; dispense in tightly closed container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release tablets, oral solution (ProCentra&reg;): Treatment of  attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages 3-16 years); treatment of narcolepsy (FDA approved in ages &ge;6 years and adults); has also been used for treatment of obesity secondary to hypothalamic-pituitary dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended/sustained release capsules (Dexedrine&reg; Spansule&reg;): Treatment of attention-deficit/hyperactivity disorder (ADHD) (FDA approved in ages 6-16 years); treatment of narcolepsy (FDA approved in ages &ge;6 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dexedrine&reg; may be confused with dextran, Excedrin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dextroamphetamine may be confused with dexamethasone",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F158817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy, hypertension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Aggression, dizziness, dyskinesia, dysphoria, euphoria, exacerbation of motor and phonic tics, headache, insomnia, mania, overstimulation, psychosis, restlessness, Tourette's syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, unpleasant taste, weight loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Impotence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Accommodation abnormalities, blurred vision",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to dextroamphetamine, other sympathomimetic amines, or any component; advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma, agitated states, history of drug abuse; concurrent use or use within 14 days of MAO inhibitors (hypertensive crisis may occur)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients receiving other sympathomimetic agents. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious cardiovascular events including sudden death may occur in patients with pre-existing structural cardiac abnormalities or other serious heart problems. Sudden death has been reported in children and adolescents; sudden death, stroke, and MI have been reported in adults. Avoid the use of amphetamines in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that could place patients at an increased risk to the sympathomimetic effects of amphetamines. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. The American  Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as dextroamphetamine, should have a thorough cardiovascular assessment prior to initiation of therapy. This assessment should include a combination of medical history, family history, and physical examination focusing on cardiovascular disease risk factors. An ECG is not mandatory but should be considered. If a child displays symptoms of cardiovascular disease, including chest pain, dyspnea, or fainting, parents should seek immediate medical care for the child. In a recent retrospective study on the possible association between stimulant medication use and sudden death in children, 564 previously healthy children who died suddenly in motor vehicle accidents were compared to a group of 564 previously healthy children who died suddenly. Two of the 564 (0.4%) children in motor vehicle accidents were taking stimulant medications compared to 10 of 564 (1.8%) children who died suddenly. While the authors of this study conclude there may be an association between stimulant use and sudden death in children, there were a number of limitations to the study and the FDA cannot conclude this information impacts the overall risk:benefit profile of these medications (Gould, 2009).  In a large retrospective cohort study involving 1,200,438 children and young adults (aged 2-24 years), none of the currently available stimulant medications or atomoxetine were shown to increase the risk of serious cardiovascular events (ie, acute MI, sudden cardiac death, or stroke) in current (adjusted hazard ratio: 0.75; 95% CI: 0.31-1.85) or former (adjusted hazard ratio: 1.03; 95% CI: 0.57-1.89) users compared to nonusers. It should be noted that due to the upper limit of the 95% CI, the study could not rule out a doubling of the risk, albeit low (Cooper, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Stimulant medications may increase blood pressure (average increase: 2-4 mm Hg) and heart rate (average increase: 3-6 bpm); some patients may experience greater increases; use stimulant medications with caution in patients with hypertension and other cardiovascular conditions that may be exacerbated by increases in blood pressure or heart rate; use is contraindicated in patients with moderate to severe hypertension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Psychiatric adverse events may occur. Stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychosis. New-onset psychosis or mania may occur with stimulant use in patients without a prior history of psychotic illness or mania, even at standard doses. Stimulants may induce mixed/manic episode in patients with bipolar disorder; patients should be screened for bipolar disorder prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, or mania) occur. May be associated with aggressive behavior or hostility; monitor for development or worsening of these behaviors.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Long-term effects in pediatric patients have not been determined. Use of stimulants in children has been associated with growth suppression; monitor growth; treatment interruption may be needed. Appetite suppression may occur; monitor weight during therapy, particularly in children. Stimulants may lower seizure threshold leading to new onset or breakthrough seizure activity; use with caution in patients with a history of seizure disorder. Visual disturbances (difficulty in accommodation and blurred vision) have been reported.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Amphetamines possess a high potential for abuse",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; misuse may cause sudden death and serious cardiovascular adverse events",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use in weight reduction programs only when alternative therapy has been ineffective; prolonged administration may lead to drug dependence; abrupt discontinuation following high doses or for prolonged periods may result in symptoms of withdrawal; avoid abrupt discontinuation in patients who have received amphetamines for prolonged periods. Amphetamines may impair the ability to engage in potentially hazardous activities. May exacerbate motor and phonic tics and Tourette's syndrome.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some tablets may contain tartrazine which may cause allergic reactions in susceptible individuals. Oral solution contains benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (\"gasping syndrome\") in neonates; avoid use of dextroamphetamine products containing benzoic acid in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alkalinizing Agents: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): Amphetamines may enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihistamines: Amphetamines may diminish the sedative effect of Antihistamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Amphetamines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethosuximide: Amphetamines may diminish the therapeutic effect of Ethosuximide. Amphetamines may decrease the serum concentration of Ethosuximide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal Acidifying Agents: May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Amphetamines may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methenamine: May decrease the serum concentration of Amphetamines. This effect is likely due to an enhanced excretion of amphetamines in the urine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Amphetamines may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Amphetamines may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acidic foods, juices, or vitamin C may decrease oral absorption. Food does not affect the rate or extent of absorption of the sustained release capsules.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6470944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have been observed in animal reproduction studies. The majority of human data is based on illicit amphetamine/methamphetamine exposure and not from therapeutic maternal use (Golub, 2005). Use of amphetamines during pregnancy may lead to an increased risk of premature birth and low birth weight; newborns may experience symptoms of withdrawal. Behavioral problems may also occur later in childhood (LaGasse, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052128\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Evaluate patients for cardiac disease prior to initiation of therapy with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment. Monitor CNS activity, blood pressure, heart rate, sleep, appetite, abnormal movements, height, weight, growth in children. Patients should be re-evaluated at appropriate intervals to assess continued need of the medication. Observe for signs/symptoms of aggression or hostility, or depression.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Amphetamines are noncatecholamine, sympathomimetic amines that promote the release of catecholamines (primarily dopamine and norepinephrine) from their storage sites in the presynaptic nerve terminals, thus increasing the amounts of circulating dopamine and norepinephrine in the cerebral cortex and reticular activating system. A less significant mechanism may include their ability to block the reuptake of catecholamines by competitive inhibition. Amphetamines also weakly inhibit the action of monoamine oxidase. They peripherally increase blood pressure and act as a respiratory stimulant and weak bronchodilator.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Oral: 60-90 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of action: Immediate release: 4-6 hours; extended release: 8 hours (Dopheide, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.5-4.6 L/kg; distributes into CNS; mean CSF concentrations are 80% of plasma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP monooxygenase and glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Immediate release: 3 hours; sustained release: 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine as unchanged drug and inactive metabolites; urinary excretion is pH dependent and is increased with acid urine (low pH)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/15/28917?source=see_link\">",
"      see \"Dextroamphetamine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Read the patient Medication Guide received with each prescription and refill of dextroamphetamine. Serious cardiac effects or psychiatric adverse effects may occur; notify physician of any heart problems, high blood pressure, or psychiatric conditions before starting therapy. May reduce the growth rate in children and has been associated with worsening of aggressive behavior; notify physician if child displays aggression or hostility; ensure that physician monitors child&rsquo;s weight and height. May impair ability to perform activities requiring mental alertness or physical coordination. May be habit-forming; avoid abrupt discontinuation after prolonged use. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination. Limit caffeine; avoid alcohol and the herbal medicine St. John's wort. May cause dry mouth. Notify physician if blurred vision occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment for ADHD should include &ldquo;drug holiday&rdquo; or periodic discontinuation in order to assess the patient's requirements, decrease tolerance, and limit suppression of linear growth and weight. Medications used to treat ADHD should be part of a total treatment program that may include other components such as psychological, educational, and social measures.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics, \"ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2011, 128(5):1007-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6263/abstract-text/22003063/pubmed\" id=\"22003063\" target=\"_blank\">",
"        22003063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: file://americanheart.mediaroon.com/index.php?s=43&amp;item=422.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      August GP, Caprio S, Fennoy I, et al, \"Prevention and Treatment of Pediatric Obesity: An Endocrine Society Clinical Practice Guideline Based on Expert Opinion,\"",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 2008, 93(12):4576-99.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6263/abstract-text/18782869/pubmed\" id=\"18782869\" target=\"_blank\">",
"        18782869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper WO, Habel LA, Sox CM, et al, \"ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2011, 365(20):1896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6263/abstract-text/22043968/pubmed\" id=\"22043968\" target=\"_blank\">",
"        22043968",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA and Pliszka SR, \"Attention-Deficit-Hyperactivity Disorder: An Update,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(6):656-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6263/abstract-text/19476419/pubmed\" id=\"19476419\" target=\"_blank\">",
"        19476419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gould MS, Walsh BT, Munfakh JL, et al, \"Sudden Death and Use of Stimulant Medications in Youths,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2009, 166(9):992-1001.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6263/abstract-text/19528194/pubmed\" id=\"19528194\" target=\"_blank\">",
"        19528194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Habel LA, Cooper WO, Sox CM, et al, \"ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-Aged Adults,\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2011, 306(24):2673-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6263/abstract-text/22161946/pubmed\" id=\"22161946\" target=\"_blank\">",
"        22161946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mason PW, Krawiecki N, and Meacham LR, \"The Use of Dextroamphetamine to Treat Obesity and Hyperphagia in Children Treated for Craniopharyngioma,\"",
"      <i>",
"       Arch Pediatr Adolesc Med",
"      </i>",
"      , 2002, 156(9):887-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6263/abstract-text/12197795/pubmed\" id=\"12197795\" target=\"_blank\">",
"        12197795",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S and AACAP Work Group on Quality Issues, \"Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6263/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson C, et al, \"Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Stimulant Drugs: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6263/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13218 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6263=[""].join("\n");
var outline_f6_7_6263=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708681\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158794\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158795\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052129\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052122\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158775\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158759\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158813\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874427\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052134\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4469949\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052133\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158819\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158817\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052138\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052121\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052120\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299162\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158768\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052141\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158770\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6470944\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052128\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052119\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052136\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052137\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052127\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052139\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13218\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13218|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/44/32454?source=related_link\">",
"      Dextroamphetamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/15/28917?source=related_link\">",
"      Dextroamphetamine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_7_6264="Benzocaine: Drug information";
var content_f6_7_6264=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Benzocaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/58/27557?source=see_link\">",
"    see \"Benzocaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=see_link\">",
"    see \"Benzocaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F139882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Americaine&reg; Hemorrhoidal [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; Baby [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; Cold Sore Therapy [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; Jr. [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Anbesol&reg; [OTC];",
"     </li>",
"     <li>",
"      Benzodent&reg; [OTC];",
"     </li>",
"     <li>",
"      Bi-Zets [OTC];",
"     </li>",
"     <li>",
"      Boil-Ease&reg; Pain Relieving [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Fizzlers&trade; [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Sore Throat &amp; Coating [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Sore Throat Plus Coating Relief [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Sore Throat [OTC];",
"     </li>",
"     <li>",
"      Cepacol&reg; Ultra Sore Throat [OTC];",
"     </li>",
"     <li>",
"      Chiggerex&reg; Plus [OTC];",
"     </li>",
"     <li>",
"      ChiggerTox&reg; [OTC];",
"     </li>",
"     <li>",
"      Dent's Extra Strength Toothache Gum [OTC];",
"     </li>",
"     <li>",
"      Dentapaine [OTC];",
"     </li>",
"     <li>",
"      Dermoplast&reg; Antibacterial [OTC];",
"     </li>",
"     <li>",
"      Dermoplast&reg; Pain Relieving [OTC];",
"     </li>",
"     <li>",
"      Detane&reg; [OTC];",
"     </li>",
"     <li>",
"      Foille&reg; [OTC];",
"     </li>",
"     <li>",
"      HDA&reg; Toothache [OTC];",
"     </li>",
"     <li>",
"      HurriCaine ONE&trade;;",
"     </li>",
"     <li>",
"      Hurricaine&reg; [OTC];",
"     </li>",
"     <li>",
"      Ivy-Rid&reg; [OTC];",
"     </li>",
"     <li>",
"      Kank-A&reg; Soft Brush [OTC];",
"     </li>",
"     <li>",
"      Lanacane&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Lanacane&reg; [OTC];",
"     </li>",
"     <li>",
"      Little Teethers&reg; [OTC];",
"     </li>",
"     <li>",
"      Medicone&reg; Hemorrhoidal [OTC];",
"     </li>",
"     <li>",
"      Mycinettes&reg; [OTC];",
"     </li>",
"     <li>",
"      Orabase&reg; with Benzocaine [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Baby Daytime and Nighttime [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Baby Teething Nighttime [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Baby Teething [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Cold Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Denture Plus [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Medicated Mouth Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Medicated Toothache [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Mouth Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Multi-Action Cold Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; PM Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; Ultra Mouth Sore [OTC];",
"     </li>",
"     <li>",
"      Orajel&reg; [OTC];",
"     </li>",
"     <li>",
"      Outgro&reg; [OTC];",
"     </li>",
"     <li>",
"      Red Cross&trade; Canker Sore [OTC];",
"     </li>",
"     <li>",
"      Rid-A-Pain Dental [OTC];",
"     </li>",
"     <li>",
"      Sepasoothe&reg; [OTC];",
"     </li>",
"     <li>",
"      Skeeter Stik&reg; [OTC];",
"     </li>",
"     <li>",
"      Sore Throat Relief [OTC];",
"     </li>",
"     <li>",
"      Sting-Kill&reg; [OTC];",
"     </li>",
"     <li>",
"      Tanac&reg; [OTC];",
"     </li>",
"     <li>",
"      Thorets [OTC];",
"     </li>",
"     <li>",
"      Trocaine&reg; [OTC];",
"     </li>",
"     <li>",
"      Zilactin&reg; Tooth &amp; Gum Pain [OTC];",
"     </li>",
"     <li>",
"      Zilactin&reg;-B [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F139883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Anbesol&reg; Baby;",
"     </li>",
"     <li>",
"      Zilactin Baby&reg;;",
"     </li>",
"     <li>",
"      Zilactin-B&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F139913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F139885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     These are general dosing guidelines; Refer to specific product labeling for dosing instructions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Bee stings, insect bites, minor burns, sunburn:",
"     </b>",
"     Topical 5% to 20%: Apply to affected area 3-4 times a day as needed. In cases of bee stings, remove stinger before treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Boils:",
"     </b>",
"     Topical 20%: Apply to affected area up to 2 times daily (maximum: 2 times/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Lubricant for passage of catheters and instruments:",
"     </b>",
"     Topical 20%: Apply evenly to exterior of instrument prior to use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mouth and gum irritation:",
"     </b>",
"     Topical (oral) 10% to 20%: Apply thin layer to affected area up to 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sore throat or mouth:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:  Allow 1 lozenge (10-15 mg) to dissolve slowly in mouth; may repeat every 2 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical (oral) spray: 5%: Apply 1 spray to affected area, then wait &ge;1 minute and spit; may repeat up to 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemorrhoids:",
"     </b>",
"     Rectal 5% to 20%: Apply externally to affected area up to 6 times daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F139897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=see_link\">",
"      see \"Benzocaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     These are general dosing guidelines; refer to specific product labeling for dosing instructions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Teething pain:",
"     </b>",
"     Children &ge;4 months: Topical (oral): 7.5% to 10%: Apply to affected gum area up to 4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Bee stings, boils, insect bites, minor burns, sunburn:",
"     </b>",
"     Topical: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Lubricant for passage of catheters and instruments:",
"     </b>",
"     Topical: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Mouth and gum irritation:",
"     </b>",
"     Topical (oral) 10% to 20%: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sore throat or mouth:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:  Children &ge;5 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Topical (oral) spray: 5%: Children &ge;6 years:",
"     <b>",
"      Note:",
"     </b>",
"     Children 6-11 years should only use under adult supervision: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hemorrhoids:",
"     </b>",
"     Rectal 5% to 20%: Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F139886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F139869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hurricaine&reg;: 20% (60 mL) [dye free; wild cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, spray, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermoplast&reg; Antibacterial: 20% (82.5 mL) [contains aloe, benzethonium chloride, menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermoplast&reg; Pain Relieving: 20% (60 mL, 82.5 mL) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ivy-Rid&reg;: 2% (85 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanacane&reg; Maximum Strength: 20% (120 mL) [contains ethanol 36%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Combination package, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Baby Daytime and Nighttime: gel, oral (Daytime Regular formula): benzocaine 7.5% (5.3 g) [1 tube] and gel, oral (Nighttime formula): benzocaine 10% (5.3 g) [1 tube]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benzodent&reg;: 20% (7.5 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; PM Maximum Strength: 20% (5.3 g, 7 g) [contains menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanacane&reg;: 6% (28 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lanacane&reg; Maximum Strength: 20% (28 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, oral: 20% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anbesol&reg;: 10% (7.1 g) [contains benzyl alcohol; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anbesol&reg; Baby: 7.5% (7.1 g) [contains benzoic acid; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anbesol&reg; Jr.: 10% (7.1 g) [contains benzyl alcohol; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anbesol&reg; Maximum Strength: 20% (7.1 g, 10 g) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dentapaine: 20% (11 g) [contains clove oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HDA&reg; Toothache: 6.5% (15 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hurricaine&reg;: 20% (30 g) [dye free; fresh mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hurricaine&reg;: 20% (30 g) [dye free; pina colada flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hurricaine&reg;: 20% (30 g) [dye free; watermelon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hurricaine&reg;: 20% (5.25 g, 30 g) [dye free; wild cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kank-A&reg; Soft Brush: 20% (2 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Little Teethers&reg;: 7.5% (9.4 g) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orabase&reg; with Benzocaine: 20% (7 g) [contains ethanol 48%; fresh mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg;: 10% (5.3 g, 7 g, 9.4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Baby Teething: 7.5% (11.9 g); 7.5% (9.4 g) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Baby Teething Nighttime: 10% (5.3 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Denture Plus: 15% (9 g) [contains ethanol 66.7%, menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Maximum Strength: 20% (5.4 g, 7 g, 9.4 g, 11.9 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Mouth Sore: 20% (5.3 g, 9.4 g, 11.9 g) [contains allantoin, benzalkonium chloride, zinc chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Multi-Action Cold Sore: 20% (9.4 g) [contains allantoin, camphor, dimethicone]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Ultra Mouth Sore: 15% (9.4 g) [contains ethanol 66.7%, menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zilactin&reg;-B: 10% (7.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Detane&reg;: 7.5% (15 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral: 20% (15 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anbesol&reg;: 10% (9.3 mL) [contains benzyl alcohol; cool mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anbesol&reg; Maximum Strength: 20% (9.3 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hurricaine&reg;: 20% (30 mL) [dye free; pina colada flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Baby Teething: 7.5% (13.3 mL) [very berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Maximum Strength: 20% (13.5 mL) [contains ethanol 44.2%, tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tanac&reg;: 10% (13 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rid-A-Pain Dental: 6.3% (30 mL) [contains ethanol 70%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral [spray]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepacol&reg; Ultra Sore Throat: 5% (22.2 mL) [sugar free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HurriCaine ONE&trade;: 20% (0.5 mL) [wild cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ChiggerTox&reg;: 2% (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Outgro&reg;: 20% (9.3 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Skeeter Stik&reg;: 5% (14 mL) [contains isopropyl alcohol, menthol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral: 6 mg (18s [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bi-Zets: 15 mg (10s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepacol&reg; Sore Throat: 15 mg (16s) [contains cetylpyridinium, menthol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepacol&reg; Sore Throat: 15 mg (16s) [contains cetylpyridinium, menthol; honey-lemon flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepacol&reg; Sore Throat: 15 mg (16s) [sugar free; contains cetylpyridinium, menthol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepacol&reg; Sore Throat &amp; Coating: 15 mg (16s) [sugar free; contains cetylpyridinium, pectin; lemon-lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepacol&reg; Sore Throat Plus Coating Relief: 15 mg (18s) [sugar free; contains cetylpyridinium, pectin; lemon-lime flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycinettes&reg;: 15 mg (12s) [sugar free; contains sodium 9 mg/lozenge; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mycinettes&reg;: 15 mg (12s) [sugar free; contains sodium 9 mg/lozenge; regular flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sepasoothe&reg;: 10 mg (6s, 24s, 100s, 250s, 500s) [sugar free; contains cetylpyridinium 0.5 mg/lozenge; wild cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sore Throat Relief: 10 mg (100s, 250s, 500s) [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Thorets: 18 mg (300s) [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trocaine&reg;: 10 mg (50s, 300s) [cherry-menthol flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anbesol&reg; Cold Sore Therapy: 20% (7.1 g) [contains allantoin, aloe, benzyl alcohol, camphor, menthol, vitamin E]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Red Cross&trade; Canker Sore: 20% (7.5 g) [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, rectal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Americaine&reg; Hemorrhoidal: 20% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Medicone&reg; Hemorrhoidal: 20% (28.4 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Boil-Ease&reg; Pain Relieving: 20% (30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chiggerex&reg; Plus: 6% (50 g) [contains aloe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Foille&reg;: 5% (3.5 g, 14 g, 28 g) [contains benzyl alcohol, chloroxylenol, corn oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pad, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sting-Kill&reg;: 20% (8s) [contains menthol, tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Paste, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orabase&reg; with Benzocaine: 20% (6 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swab, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hurricaine&reg;: 20% (8s, 72s) [dye free; wild cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Baby Teething: 7.5% (12s) [berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Cold Sore: 20% (12s) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Medicated Mouth Sore: 20% (8s, 12s) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orajel&reg; Medicated Toothache: 20% (8s, 12s) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zilactin&reg; Tooth &amp; Gum Pain: 20% (8s) [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Swab, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Boil-Ease&reg; Pain Relieving: 20% (12s) [contains tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sting-Kill&reg;: 20% (5s) [contains menthol, tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally dissolving, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cepacol&reg; Fizzlers&trade;: 6 mg (12s) [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Wax, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dent's Extra Strength Toothache Gum: 20% (1 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F139856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Lozenge, liquid",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7714363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid application to large areas of broken skin, especially in children. When possible, apply to clean, dry area. When administering a spray formulation, the number of sprays administered and the length of each spray should be monitored and recorded.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F139870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Temporary relief of pain associated with pruritic dermatosis, pruritus, minor burns, acute congestive, bee stings, and insect bites; mouth and gum irritations (toothache, minor sore throat pain, canker sores, dentures, orthodontia, teething, mucositis, stomatitis); sunburn; hemorrhoids; anesthetic lubricant for passage of catheters and endoscopic tubes",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F139920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Orabase&reg;  may be confused with Orinase",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F139911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Burning, contact dermatitis, edema, erythema, pruritus, rash, stinging, tenderness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F139873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to benzocaine, other ester-type local anesthetics, or any component of the formulation; secondary bacterial infection of area; ophthalmic use",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F139860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia: Has been reported following topical use, particularly with higher concentration (14% to 20%) spray formulations applied to the mouth or mucous membranes. When applied as a spray to the mouth or throat, multiple sprays (or sprays of longer than indicated duration) are not recommended. Use caution with breathing problems (asthma, bronchitis, emphysema, in smokers), inflamed/damaged mucosa, heart disease, children &lt;6 months of age, and hemoglobin or enzyme abnormalities (glucose-6-phosphate dehydrogenase deficiency, hemoglobin-M disease, NADH-methemoglobin reductase deficiency, pyruvate-kinase deficiency). Alternatives to benzocaine sprays, such as topical lidocaine preparations, should be considered for patients at higher risk of this reaction. The classical clinical finding of methemoglobinemia is chocolate brown-colored arterial blood. However, suspected cases should be confirmed by co-oximetry, which yields a direct and accurate measure of methemoglobin levels. Standard pulse oximetry readings or arterial blood gas values are not reliable. Clinically significant methemoglobinemia requires immediate treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Due to the heightened risk of methemoglobinemia, not recommended for use in patients &lt;2 years of age unless under the advice and supervision by a healthcare professional.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self-medication, notify healthcare provider if condition worsens or does not improve within the timeframe noted on the product labeling or if accompanied by additional symptoms (eg, swelling, rash, headache, nausea, vomiting, or fever). Do not use topical products on open wounds; avoid contact with the eyes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heart beats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to  cover the skin following application.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F139865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F139866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1959662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F139888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16257718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if benzocaine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering benzocaine to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9729964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Dermoplast Antibacterial External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-0.2% (78 g): $5.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Dermoplast External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-0.5% (56 g): $5.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Ivy-Rid External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15-5-9% (82.5 mL): $4.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol",
"     </b>",
"     (Lanacane Anti-Bacterial External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-0.2% (99 g): $4.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lanacane External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6-0.2% (28 g): $3.42",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Lanacane Maximum Strength External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20-0.2% (28 g): $4.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Vagisil Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-2% (30 g): $3.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Anbesol JR Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (9 g): $4.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Anbesol Maximum Strength Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (9 g): $5.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Anbesol Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (9 g): $4.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Baby Anbesol Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (9 g): $4.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Baby Orajel Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (9.4 g): $4.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Baby Orajel Nighttime Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (5.3 g): $4.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Benz-O-Sthetic Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (29 g): $7.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Dentapaine Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (11 g): $3.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Detane External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (14.1 g): $3.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Hurricaine Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (30 g): $9.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Orabase Maximum Strength Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (7 g): $4.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Orajel Denture Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (5.63 g): $2.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Orajel Dry Mouth Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     18% (42 g): $4.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Orajel Maximum Strength Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (5.3 g): $4.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Orajel Mouth-Aid Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.02-20-0.1% (5.63 g): $3.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Orajel Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (7 g): $3.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (OraStat Maximum Strength Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (14.2 g): $2.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Retre-Gel Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-1-20% (7.5 g): $4.32",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Zilactin Baby Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (9.4 g): $3.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Zilactin-B Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (7.1 g): $8.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Anbesol Maximum Strength Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (12 mL): $5.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Anbesol Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (12 mL): $4.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Baby Orajel Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5% (13.3 mL): $4.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Benz-O-Sthetic Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (56 g): $23.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Cepacol Dual Relief Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-33% (22.2 mL): $3.33",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Chiggertox External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.1% (30 mL): $1.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Orajel Maximum Strength Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (13.3 mL): $5.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Skeeter Stik External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-1% (14.1 mL): $1.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Bi-Zets/Benzotroches Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (10): $2.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Cepacol Sensations Cooling Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-9 mg (20): $2.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Cepacol Sensations Hydra Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3 mg (20): $2.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Cepacol Sensations Warming Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (20): $2.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Cepacol Sore Throat + Coating Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-5 mg (16): $2.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Cepacol Sore Throat + Cough Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-7.5 mg (16): $2.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Cepacol Sore Throat Max Numb Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-3.6 mg (16): $2.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-4 mg (16): $2.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Cepacol Sore Throat Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-2.1 mg (18): $2.83",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15-3.6 mg (576): $44.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Sep-A-Soothe Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5-10 mg (2): $0.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Trocaine Throat Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (1): $0.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Anacaine External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (30 g): $13.45",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Boil-Ease External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-1.86-0.44% (30 g): $5.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Chiggerex External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (52.5 g): $1.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Foille External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5-0.1% (28 g): $2.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paste",
"     </b>",
"     (Orabase-B Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (6 g): $3.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Benz-O-Sthetic Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (30 mL): $7.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hurricaine Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (30 mL): $9.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (57 g): $36.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (HurriCaine One Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (2): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Kank-A Mouth Pain Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (9.75 mL): $3.67",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension (reconstituted)",
"     </b>",
"     (OraMagic Plus Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (60 mL): $7.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Swab",
"     </b>",
"     (Benz-O-Sthetic Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (2): $2.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Swab",
"     </b>",
"     (Boil-Ease External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (12): $5.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Swab",
"     </b>",
"     (Hurricaine Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (72): $30.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Cepacol Fizzlers Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (12): $4.81",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3880690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor patients for signs and symptoms of methemoglobinemia such as pallor, cyanosis, nausea, muscle weakness, dizziness, confusion, agitation, dyspnea and tachycardia. The classical clinical finding of methemoglobinemia is chocolate brown-colored arterial blood. However, suspected cases should be confirmed by co-oximetry, which yields a direct and accurate measure of methemoglobin levels. Standard pulse oximetry readings or arterial blood gas values are not reliable. Clinically significant methemoglobinemia requires immediate treatment.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F139876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AAA Spray (GB);",
"     </li>",
"     <li>",
"      Anaestherit (AT);",
"     </li>",
"     <li>",
"      Anaesthesin (DE);",
"     </li>",
"     <li>",
"      Auralyt (MX);",
"     </li>",
"     <li>",
"      Baby Orajel (PL);",
"     </li>",
"     <li>",
"      Babydent (CZ);",
"     </li>",
"     <li>",
"      Claudemor (PT);",
"     </li>",
"     <li>",
"      Dentispray (ES, PL);",
"     </li>",
"     <li>",
"      Dermopur (PL);",
"     </li>",
"     <li>",
"      Dolodent (DK);",
"     </li>",
"     <li>",
"      Etylu Aminobenzoesan (PL);",
"     </li>",
"     <li>",
"      Freez-Eze Throat Anesthetic Gel (SG);",
"     </li>",
"     <li>",
"      Gartricin (ES);",
"     </li>",
"     <li>",
"      Gengivarium (IT);",
"     </li>",
"     <li>",
"      Graneodin-B (MX);",
"     </li>",
"     <li>",
"      Hurricaine (ES, LU);",
"     </li>",
"     <li>",
"      Hurricaine Gel (IL);",
"     </li>",
"     <li>",
"      Hurricane Spray (SG);",
"     </li>",
"     <li>",
"      Lanacane (ES);",
"     </li>",
"     <li>",
"      Lodoc (AR);",
"     </li>",
"     <li>",
"      Nani Pre Dental (ES);",
"     </li>",
"     <li>",
"      Octicaina (CO);",
"     </li>",
"     <li>",
"      Orajel (CH, PL);",
"     </li>",
"     <li>",
"      Otisyn (FI);",
"     </li>",
"     <li>",
"      Topicaine (AU);",
"     </li>",
"     <li>",
"      Ultracare (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F139859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ester local anesthetic blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F139872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Topical: Poor to intact skin; well absorbed from mucous membranes and traumatized skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (to a lesser extent) and plasma via hydrolysis by cholinesterase",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Anderson ST, Hajduczek J, and Barker SJ, &ldquo;Benzocaine-Induced Methemoglobinemia in an Adult: Accuracy of Pulse Oximetry With Methemoglobinemia,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1988, 67(11):1099-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6264/abstract-text/3189900/pubmed\" id=\"3189900\" target=\"_blank\">",
"        3189900",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bachmann P, Berthier JC, Storme B, et al, &ldquo;Methemoglobinemia From Ingestion of Benzocaine. A Case of Pediatric Intoxication,&rdquo;",
"      <i>",
"       J Toxicol Clin Exp",
"      </i>",
"      , 1986, 6(2):123-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6264/abstract-text/3783485/pubmed\" id=\"3783485\" target=\"_blank\">",
"        3783485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Guertler AT and Pearce WA, &ldquo;A Prospective Evaluation of Benzocaine-Associated Methemoglobinemia in Human Beings,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1994, 24(4):628-30.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TJ, Walsh CS, and Cohen MR, et al , &ldquo;Reported Adverse Event Cases of Methemoglobinemia Associated With Benzocaine Products,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2004, 164(11):1192-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/7/6264/abstract-text/15197044/pubmed\" id=\"15197044\" target=\"_blank\">",
"        15197044",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rynn KO, Jahns BE, and Sabbun R, &ldquo;Acute Myocardial Infarction (AMI) Secondary to Benzocaine-Induced Methemoglobinemia,&rdquo;",
"      <i>",
"       Clin Toxicol",
"      </i>",
"      , 1995, 33(5):495.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shua-Haim JR and Gross JS, &ldquo;Methemoglobinemia Toxicity From Topical Benzocaine Spray,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1995, 43(5):590.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stein JM and Warfield CA, &ldquo;Local Anesthetics: Principles of Safe Use,&rdquo;",
"      <i>",
"       Hosp Pract (Off Ed)",
"      </i>",
"      , 1983, 18(5):73-8.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9092 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6264=[""].join("\n");
var outline_f6_7_6264=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139882\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139883\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139913\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139885\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139897\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139886\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139869\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139856\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7714363\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139870\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139920\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139911\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139873\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139860\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298833\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139865\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139866\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1959662\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139888\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16257718\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729964\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323014\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3880690\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139876\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139859\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F139872\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9092\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9092|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/58/27557?source=related_link\">",
"      Benzocaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/19/11574?source=related_link\">",
"      Benzocaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_7_6265="Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa";
var content_f6_7_6265=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical features, and diagnosis of hidradenitis suppurativa",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/7/6265/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6265/contributors\">",
"     Lynne J Margesson, MD, FRCPC, FAAD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6265/contributors\">",
"     F William Danby, MD, FRCPC, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/7/6265/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6265/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6265/contributors\">",
"     Mark V Dahl, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/7/6265/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6265/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/7/6265/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hidradenitis suppurativa (HS, from the Greek hidros = sweat and aden = glands) is also known as acne inversa, and in older literature as Verneuil's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is a chronic follicular occlusive disease involving the intertriginous skin of the axillary, groin, perianal, perineal, and inframammary regions.",
"   </p>",
"   <p>",
"    The clinical course is highly variable, ranging from just a few recurrent, isolated nodules to deep fluctuant cysts",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    draining sinuses and fistulae leading to bands of severe scar formation. Early HS lesions often mimic other disorders; misdiagnosis (usually as \"boils\") and fragmented care can result in progression to chronic, disabling, end-stage HS, which can have a profound impact on the quality of life and can only be managed surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis, clinical manifestations, and diagnosis of HS will be discussed here. Treatment is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24266?source=see_link\">",
"     \"Treatment of hidradenitis suppurativa\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported prevalence of HS is as high as 4 percent, depending on the definition used [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. There is no racial predilection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. HS affects more women than men: the sex ratio is 3:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], but disease in certain sites shows gender preferences. The onset of symptoms usually occurs between puberty and age 40, with average age of onset in the second or third decade of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histologic findings of hidradenitis suppurativa include [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/3,15,16\">",
"     3,15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spongiform infundibulofolliculitis in very early lesions",
"     </li>",
"     <li>",
"      Occlusion of the infundibular portion of the follicle by follicular hyperkeratosis and follicular epithelial hyperplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Dilation of the follicle with secondary stasis in apocrine glands",
"     </li>",
"     <li>",
"      Extensive perifolliculitis",
"     </li>",
"     <li>",
"      Cystic epithelium-lined structures containing hair shafts",
"     </li>",
"     <li>",
"      Abscess formation leading to destruction of pilosebaceous units and, at times, other nearby adnexal structures, particularly apocrine glands",
"     </li>",
"     <li>",
"      Epithelial strands forming sinus tracts and subcutaneous abscesses",
"     </li>",
"     <li>",
"      Inflammation with extensive fibrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unlike acne, significant sebaceous gland involvement is",
"    <strong>",
"     NOT",
"    </strong>",
"    a component of HS, either by histologic examination or by measuring the sebum secretion rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology and pathogenesis of HS are not fully understood. The most likely mechanism responsible for initial development of HS is occlusion of the terminal parts of the follicular acroinfundibulum (rather than the apocrine gland) due to a defect in terminal differentiation that impedes follicular epithelial shedding [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/3,15,20-23\">",
"     3,15,20-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Circulating androgens may play a role in the development of HS through stimulating the process of follicular occlusion. It has been hypothesized that elevated serum levels of insulin and insulin-like growth factor in patients with HS may contribute to sensitization follicular androgen receptors, a concept that may explain the link between obesity and an increased risk for HS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Predisposing factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    As a consequence of follicular occlusion secondary to abnormal keratinocyte differentiation and failure of keratinocytes to shed, the follicular duct expands as keratinocytes accumulate and the wall of the follicle eventually ruptures. The results of a histological study that compared tissue specimens from patients with HS and normal controls suggest that a preexisting defect in the follicular wall at the sebofollicular junction in individuals with HS may contribute to an increased risk for follicular rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Follicular rupture results in the release of numerous antigens and other inflammatory stimuli that trigger elements of the adaptive and innate immune systems, leading to the development of an acute inflammatory response in the surrounding tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/3,15,21-23,26-28\">",
"     3,15,21-23,26-28",
"    </a>",
"    ]. Fragments of the follicular epithelial wall, including stem cells from the bulge region of the follicle, also are released during follicular rupture [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/29\">",
"     29",
"    </a>",
"    ]. The combination of acute reactive inflammation and cellular proliferation may account for the development and spread of the dermal and subcutaneous abscesses and sinus tracts that occur in HS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/30\">",
"     30",
"    </a>",
"    ]. Chronic inflammation with histiocytes and giant cells occurs as a secondary event, and results in chronic tissue destruction through a foreign body-like reaction.",
"   </p>",
"   <p>",
"    The significance of bacterial infection in HS is controversial. Although bacterial superinfection with streptococci, staphylococci, and coliforms was considered part of the pathogenesis of the disorder, cultures from lesions are frequently sterile and antibiotics are not curative. The bacterial findings are considered by some experts to be either contaminants from normal skin flora or a result of secondary infection in a previously sterile process [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Predisposing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired and genetic factors predispose to development of HS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Obesity &mdash;",
"      </strong>",
"      Shearing forces from obesity and obesity-related hormonal effects have been considered contributors to the development of HS [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/32\">",
"       32",
"      </a>",
"      ]. The disease affects thin people; however, being overweight results in significantly more severe disease [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/33\">",
"       33",
"      </a>",
"      ]. In one series of 302 patients with HS, a higher body mass index was significantly associated with greater disease severity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Endocrine &mdash;",
"      </strong>",
"      A relationship has been proposed between sex hormones (mainly androgens) and HS [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/35\">",
"       35",
"      </a>",
"      ]. Several observations support this hypothesis: HS is seldom seen before puberty, childhood cases have been associated with precocious puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/36\">",
"       36",
"      </a>",
"      ], and new onset HS has been reported in postmenopausal women [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/37-40\">",
"       37-40",
"      </a>",
"      ]. Pregnancy and menstruation do not have a consistent effect on the disease.",
"      <br/>",
"      <br/>",
"      Hyperandrogenism has been suggested as a causal factor in women [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/23,37-41\">",
"       23,37-41",
"      </a>",
"      ], but the association between androgens and HS remains controversial. A report on the endocrine status of 66 women with HS found no evidence of biochemical hyperandrogenism when compared to controls matched for age, weight, and hirsutism [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/37\">",
"       37",
"      </a>",
"      ]. Similar findings were noted in another study [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/9\">",
"       9",
"      </a>",
"      ]. On the other hand, anti-androgen therapy is of some benefit in HS patients.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       Finasteride",
"      </a>",
"      , a selective inhibitor of the type II isomer of 5 alpha-reductase was used to treat seven cases of HS (five women and two men) as monotherapy; six patients improved, supporting the role of androgens [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/42\">",
"       42",
"      </a>",
"      ]. Additional evidence supporting the influence of androgens on HS derives from observations that HS in children occurs in those who also have premature adrenarche or early puberty [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/43\">",
"       43",
"      </a>",
"      ] and that HS does not occur in eunuchs or eunuchoids. Finally, in anecdotal reports,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      , an inhibitor of both type I and II isomers of 5 alpha-reductase, was an effective treatment of HS when used alone or with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      The main mechanism proposed for the possible role of androgen dependence in HS lies in end-organ sensitivity, rather than in plasma levels. Women can develop HS while taking oral contraceptives, especially when androgenic progestins are used [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/35\">",
"       35",
"      </a>",
"      ]. Keratinocytes from the acroinfundibulum express the key enzymes involved in in situ metabolism of androgens (in situ synthesis of weaker androgens, their transformation into testosterone and its reduction to DHT) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/44\">",
"       44",
"      </a>",
"      ]. Although this enzymatic activity in HS has not yet been investigated, HS has been associated with other endocrine disorders, such as diabetes, Cushing's disease, and acromegaly [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/38,45\">",
"       38,45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Arguing against a role for androgens in HS are observations that, although acne is more prevalent and severe in males, HS is predominantly a female disease (13:5).",
"     </li>",
"     <li>",
"      <strong>",
"       Genetic &mdash;",
"      </strong>",
"      There appears to be a familial predisposition to HS [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/9,46-48\">",
"       9,46-48",
"      </a>",
"      ]. In one report, a positive family history of HS was present more often in patients than controls matched for age and sex (26 versus 2 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/9\">",
"       9",
"      </a>",
"      ]. Other studies examined 62 affected persons (40 females and 22 males) in 11 families [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. A pattern consistent with autosomal dominant inheritance was noted. There may be a hormonal influence on gene expression, which could account for the female predominance of the disease.",
"      <br/>",
"      <br/>",
"      The first two candidate genetic loci for HS have been identified, but not all affected families link to these loci, suggesting that HS is a genetically heterogeneous disease with potentially three or more genes involved [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Infection &mdash;",
"      </strong>",
"      Bacteria have traditionally been implicated in the pathogenesis of HS. Various bacteria, staphylococci, streptococci, and Escherichia coli are found in early HS. In chronic disease with sinuses and draining abscesses, anaerobic bacteria (eg, Proteus mirabilis) may be found. Infection can be responsible for associated acute complications, such as cellulitis, but are not primary causative factors [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/32,51\">",
"       32,51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Immune factors &mdash;",
"      </strong>",
"      Pathologic examination of excised early lesions demonstrates T-lymphocyte-predominant perifollicular inflammation suggestive of a cell-mediated immune reaction [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/15\">",
"       15",
"      </a>",
"      ]. In one series, the early lesions were associated with a sharp decline in the",
"      <span class=\"nowrap\">",
"       T-helper/suppressor",
"      </span>",
"      ratio in the plasma. However, immunologic studies in patients with HS have shown mixed results [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/52-55\">",
"       52-55",
"      </a>",
"      ]. As examples, systemic cell mediated immunity and neutrophil function were normal in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/52\">",
"       52",
"      </a>",
"      ], while a marked reduction in T lymphocyte counts was found in another [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Diet &mdash;",
"      </strong>",
"      High glycemic diets and milk consumption may contribute to increased sensitivity of follicular receptors to androgens through a mechanism that involves a response to serum elevations of insulin and insulin-like growth factor [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/24\">",
"       24",
"      </a>",
"      ]. Additional studies are necessary to determine the role of diet in HS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=see_link\">",
"       \"Dietary carbohydrates\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other &mdash;",
"      </strong>",
"      HS has been associated with several cutaneous abnormalities and nonprescription drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/14,48,56-70\">",
"       14,48,56-70",
"      </a>",
"      ]. Smoking is strongly associated with HS epidemiologically [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/71\">",
"       71",
"      </a>",
"      ], and data suggest a causative role for the non-neuronal cholinergic (nicotinic) system, which may promote infundibular epithelial hyperplasia, with subsequent follicular plugging [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/10,61,72\">",
"       10,61,72",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      HS is a rare side effect of drug use. It has developed after the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      and androgenic progestins in oral contraceptives [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/35,73\">",
"       35,73",
"      </a>",
"      ]. We have observed single cases in which intramuscular",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/47/25336?source=see_link\">",
"       levonorgestrel",
"      </a>",
"      in an intrauterine device precipitated or worsened HS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HS affects the following sites in order of frequency: axillae (",
"    <a class=\"graphic graphic_picture graphicRef77990 \" href=\"UTD.htm?37/25/38289\">",
"     picture 1",
"    </a>",
"    ), inguinal area, inner thighs, perianal and perineal areas, mammary and inframammary region, buttocks, pubic region, scrotum, vulva (",
"    <a class=\"graphic graphic_picture graphicRef65884 graphicRef65188 \" href=\"UTD.htm?6/9/6297\">",
"     picture 2A-B",
"    </a>",
"    ), chest, scalp, and retroauricular area. The axillae, groin, and inframammary regions are the commonest areas affecting women; perineal and perianal skin areas are more commonly involved in men [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The onset of HS is typically at puberty. Onset can be insidious, with solitary, painful nodules that can last weeks to months. These lesions may develop as recurrent episodes of inflammation. They are commonly incorrectly diagnosed as \"boils\" or \"furunculosis.\" Unlike furuncles, HS lesions are often deep, round (not pointed), and without the central necrosis that leads to spontaneous drainage of furuncles. The average duration of a single lesion is seven days and the lesions average two per month, with a variable range of one per year to 30 per month. Most patients have at least one active lesion at all times.",
"   </p>",
"   <p>",
"    The lesions are painful and can be so totally disruptive that the patient cannot walk or sit without pain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/75\">",
"     75",
"    </a>",
"    ]. The nodules can remain sore, deep, and indolent, but most often they develop into abscesses, rupture externally, and drain purulent material. Drainage relieves pain. With multiple lesions in one area, chronic intercommunicating draining sinuses can form, with intermittent release of seropurulent, and at times malodorous, bloody discharge. These abscesses can burrow and rupture into contiguous areas.",
"   </p>",
"   <p>",
"    Healing can occur. The appearance of healed areas ranges from individual pitted scars for the smaller lesions to dense fibrotic bands, indurated thick, scarred plaques affecting the whole axilla and groin area. Chronic lymphedema may develop due to lymphatic disruption.",
"   </p>",
"   <p>",
"    HS can be graded according to Hurley's clinical staging system (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnosis'",
"    </a>",
"    below). About 75 percent of HS patients are in stage I, 24 percent in stage II, and 1 percent in stage III.",
"   </p>",
"   <p>",
"    There is considerable disruption and impairment of the quality of life for the HS patient [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/76\">",
"     76",
"    </a>",
"    ]. In one review, HS was found to be one of the most distressing dermatological conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/77\">",
"     77",
"    </a>",
"    ]. The unpredictable discharge, the necessary dressings, and their accompanying odor are embarrassing, humiliating, and result in social isolation, depression, failed relationships, and sometimes loss of employment.",
"   </p>",
"   <p>",
"    Anogenital HS may extend into the anal canal and may form perianal and perirectal sinuses. HS and anogenital Crohn's disease are similar in appearance and may be associated with (or mistaken for) each another [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/63,78\">",
"     63,78",
"    </a>",
"    ]. However, HS is typically distal to the dentate line in the luminal tissue, while Crohn's disease can be proximal. Minor functional abnormalities of the gut mucosa or failure of gut IgA to inactivate bacterial or dietary antigens passing through the small intestine may result in the formation of IgA immune complexes; these complexes may subsequently be deposited in the skin, with resultant disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/64\">",
"     64",
"    </a>",
"    ]. An association with Behcet&rsquo;s disease has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=see_link\">",
"     \"Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of HS is based upon the characteristic clinical manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/8\">",
"     8",
"    </a>",
"    ]; biopsy is neither required nor diagnostic. Specific diagnostic criteria do not exist.",
"   </p>",
"   <p>",
"    There are three main diagnostic features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Typical lesions &mdash; multiple deep-seated nodules (blind boils), comedones,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fibrosis",
"     </li>",
"     <li>",
"      Typical locations &mdash; bilateral involvement of axillae, groin, inframammary areas",
"     </li>",
"     <li>",
"      Relapses and chronicity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Individual lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lesions are classified by appearance, location and behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Primary (early) lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most frequently, the first lesion is a solitary, painful deep-seated nodule (0.5-2 cm in diameter) in an intertriginous area. The lesion is round and deep without the \"pointing\" or central necrosis of a furuncle [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/8\">",
"     8",
"    </a>",
"    ]. It may resolve spontaneously within several days or persist as a non-tender nodule with subsequent recurrences of inflammatory episodes over weeks or months without any evidence of suppuration.",
"   </p>",
"   <p>",
"    The lesion usually progresses to form an abscess, which may open superficially to the surface, yielding purulent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    serosanguineous drainage (",
"    <a class=\"graphic graphic_picture graphicRef69605 \" href=\"UTD.htm?6/12/6338\">",
"     picture 3",
"    </a>",
"    ). The abscess may fail to drain and become painful, necessitating surgical drainage. Simple drainage yields only temporary relief; the disease has a strong tendency to recur at exactly the same site. Diagnosis is frequently missed at this stage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Secondary lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence at the same site, appearance of adjacent new lesions, coalescence of existing lesions, and fibrosis of the surrounding skin characterize secondary lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/8\">",
"     8",
"    </a>",
"    ]. Sinus tracts are typical findings (",
"    <a class=\"graphic graphic_picture graphicRef52570 \" href=\"UTD.htm?36/6/36975\">",
"     picture 4",
"    </a>",
"    ). These persist for months or years and contribute to symptomatology. Sinus tracts are not always palpable, becoming apparent only when a substance injected into a lesion appears at a site distant from the injection point. Because of the chronic inflammation and disruption of the sinus tracts, multiple pyogenic granulomas may rarely appear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Tertiary lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most often recognized stage of HS involves unique hypertrophic fibrous scarring leading to indurated plaques in which the inflammatory nodules and sinuses remain active. This process may involve the entire zone of involved skin, forming a subcutaneous network of sinuses that can be palpated on clinical examination. In more lax, flexural skin (axillae), this bridged scarring results in thick, linear, rope-like bands. Such scarring may decrease the mobility of the arm or produce lymphatic obstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Comedones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Closed comedones (white heads) rarely are present in areas of HS. Open comedones (black heads) are also absent in early disease, but may appear in long-lasting HS, usually as multi-headed comedones found at the openings of burnt-out lesions or sinuses. These are the classic \"tombstone comedones\" [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a few processes produce recurrent abscesses and sinus tract formation with a characteristic distribution in the intertriginous skin. Age of onset and lesion location help to distinguish HS from other disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Follicular pyodermas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follicular pyodermas (eg, folliculitis, furuncles, carbuncles) are infections arising from a hair follicle. However, they are generally quite superficial, heal quickly, and do not result in the widespread scarring, pitting, and induration observed with HS. Pilonidal cysts are inflammatory and may be confused with such infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Granuloma inguinale",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granuloma inguinale (Donovanosis) usually occurs on the vulva, penis, scrotum, glans, inguinal folds, or perianal skin (",
"    <a class=\"graphic graphic_picture graphicRef71166 \" href=\"UTD.htm?39/51/40755\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/81\">",
"     81",
"    </a>",
"    ]. Lesions usually present as red ulcers with granulation tissue that bleed easily and have a foul odor. The presence of an enlarging ulcer with an undermined border suggests this diagnosis over HS.",
"   </p>",
"   <p>",
"    The causative agent of granuloma inguinale is Klebsiella granulomatis; the organism cannot be cultured. Diagnosis requires visualization of dark-staining Donovan bodies on tissue crush preparation or biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Crohn's disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perianal and vulvar manifestations of Crohn's disease include abscesses, rectoperineal and rectovaginal fistulae, sinus tracts, fenestrations, and scarring, as well as \"knife-cut\" ulcers in the inguinal, genitocrural, and interlabial folds (",
"    <a class=\"graphic graphic_picture graphicRef81233 graphicRef58354 \" href=\"UTD.htm?21/37/22105\">",
"     picture 6A-B",
"    </a>",
"    ). Differentiation of HS from Crohn's disease depends upon a previous history of gastrointestinal involvement in the latter but, as noted above, there may be association between the two disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=see_link\">",
"     \"Perianal complications of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Acne",
"    </span>",
"    &nbsp;&mdash;&nbsp;HS shares several features with acne: follicular hyperkeratinization leading to occlusion, sinus tracts, scarring, and comedo-like lesions. However, acne is a disease of the pilosebaceous follicles; it is responsive to medical therapy; and its distribution (eg, face, upper chest, and back) is markedly different from that of HS (eg, axillae, groin, buttocks, and inframammary fossae). Both are due to suppurative inflammation of androgen-sensitive terminal hair follicles with HS leading to secondary involvement of apocrine, eccrine, and sebaceous glands. HS is a chronic relapsing inflammatory process, poorly responsive to medical or surgical therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     HURLEY'S CLINICAL STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;This is a system to classify disease severity and to direct management [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage I &mdash; Abscess formation, single or multiple, without sinus tracts and cicatrization. Managed with drug therapy.",
"     </li>",
"     <li>",
"      Stage II &mdash; Recurrent abscesses with tract formation and cicatrization. Single or multiple widely separated lesions. Managed with drug therapy and limited excision of recalcitrant lesions.",
"     </li>",
"     <li>",
"      Stage III &mdash; Diffuse or near diffuse involvement, or multiple interconnected tracts and abscesses across the entire area. Unlikely to benefit from medical therapy; wide surgical excision is recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of long-standing, untreated disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fistulae (rare) into urethra, bladder, rectum, and peritoneum [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Strictures and contractures [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Arthropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/83\">",
"       83",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Malaise, depression, and suicide",
"     </li>",
"     <li>",
"      Lymphatic obstruction, lymphedema of limbs and genitalia",
"     </li>",
"     <li>",
"      Long-term effects of chronic suppuration including anemia, hypoproteinemia and amyloidosis",
"     </li>",
"     <li>",
"      Squamous cell carcinoma (SCC) arising in HS is rare, but has been reported in at least 52 cases [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/65-68,84\">",
"       65-68,84",
"      </a>",
"      ]. One-half of these patients died of metastatic disease. Human papilloma virus (HPV) infection may be an important contributing factor to the development of SCC in lesions of HS [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lumbosacral epidural abscess [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sacral bacterial osteomyelitis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2318475\">",
"    <span class=\"h1\">",
"     ASSOCIATED CONDITIONS AND COMORBIDITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of conditions, including inflammatory, neoplastic, and genetic disorders have been associated with hidradenitis suppurativa [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6265/abstract/85\">",
"     85",
"    </a>",
"    ]. A table listing disorders that have been associated with HS is provided (",
"    <a class=\"graphic graphic_table graphicRef75490 \" href=\"UTD.htm?30/55/31611\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/23/22897?source=see_link\">",
"       \"Patient information: Hidradenitis suppurativa (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hidradenitis suppurativa (HS) refers to a chronic, suppurative, subcutaneous process that results from occlusion of follicles, secondary inflammation and sometimes infection of pilosebaceous and (secondarily) apocrine glands. It is neither contagious nor due to poor hygiene. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The disease affects the axillae most commonly; genitofemoral region; gluteal folds and perianal region; infraumbilical midline, inframammary and periareolar areas. The usual presentation is of small painful subcutaneous nodules, but early symptoms consisting of pruritus, erythema, burning, and local hyperhidrosis have been reported. Nodules develop and may rupture, discharging purulent, sometimes malodorous material and forming sinus tracts. Unruptured nodules eventually turn into indurated inflammatory masses. Hyperpigmentation, scars, and pitting of the skin occur over time. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of HS is based upon characteristic clinical manifestations. Biopsy is neither diagnostic nor required unless there is suspicion of malignancy. The clinician should have a high index of suspicion for the disease in individuals with recurrent \"boils\" in intertriginous areas after puberty, despite antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/1\">",
"      Sellheyer K, Krahl D. \"Hidradenitis suppurativa\" is acne inversa! An appeal to (finally) abandon a misnomer. Int J Dermatol 2005; 44:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/2\">",
"      Bazex J, Bayle P, San B. Hidradenitis suppurativa is acne inversa. Int J Dermatol 2007; 46:330; author reply 330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/3\">",
"      Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium, rather than apocrine glands. Br J Dermatol 1990; 122:763.",
"     </a>",
"    </li>",
"    <li>",
"     Plewig G, StegerM. Acne inversa (alias acne triad, acne tetrad or hidradenitis suppurativa). In: Acne and related disorders, Marks R, Plewig G (Eds), Martin Dunitz, London 1991. Vol 345.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/5\">",
"      Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2009; 23:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/6\">",
"      Wiseman MC. Hidradenitis suppurativa: a review. Dermatol Ther 2004; 17:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/7\">",
"      Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009; 60:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/8\">",
"      Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012; 366:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/9\">",
"      Jemec GB. The symptomatology of hidradenitis suppurativa in women. Br J Dermatol 1988; 119:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/10\">",
"      Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol 2008; 59:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/11\">",
"      Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996; 35:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/12\">",
"      Jemec GB, Heidenheim M, Nielsen NH. A case-control study of hidradenitis suppurativa in an STD population. Acta Derm Venereol 1996; 76:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/13\">",
"      Harrison BJ, Mudge M, Hughes LE. Recurrence after surgical treatment of hidradenitis suppurativa. Br Med J (Clin Res Ed) 1987; 294:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/14\">",
"      Wiltz O, Schoetz DJ Jr, Murray JJ, et al. Perianal hidradenitis suppurativa. The Lahey Clinic experience. Dis Colon Rectum 1990; 33:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/15\">",
"      Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa. A clinicopathological study of early lesions. Br J Dermatol 1996; 135:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/16\">",
"      Heller DS, Haefner HK, Hameed M, Lieberman RW. Vulvar hidradenitis suppurativa. Immunohistochemical evaluation of apocrine and eccrine involvement. J Reprod Med 2002; 47:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/17\">",
"      von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011; 164:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/18\">",
"      Jemec GB, Gniadecka M. Sebum excretion in hidradenitis suppurativa. Dermatology 1997; 194:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/19\">",
"      Jemec GB, Hansen U. Histology of hidradenitis suppurativa. J Am Acad Dermatol 1996; 34:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/20\">",
"      Brown TJ, Rosen T, Orengo IF. Hidradenitis suppurativa. South Med J 1998; 91:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/21\">",
"      Attanoos RL, Appleton MA, Douglas-Jones AG. The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J Dermatol 1995; 133:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/22\">",
"      Jemec GB, Thomsen BM, Hansen U. The homogeneity of hidradenitis suppurativa lesions. A histological study of intra-individual variation. APMIS 1997; 105:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/23\">",
"      Ostlere LS, Langtry JA, Mortimer PS, Staughton RC. Hidradenitis suppurativa in Crohn's disease. Br J Dermatol 1991; 125:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/24\">",
"      Melnik BC. Acneigenic stimuli converge in phosphoinositol-3 Kinase/Akt/Foxo1 signal transduction. J Clin Exp Dermatol 2010; 1:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/25\">",
"      William Danby F, Jemec GB, Marsch WC, von Laffert M. Preliminary findings suggest&nbsp;hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/26\">",
"      Gordon SW. Hidradenitis suppurativa: a closer look. J Natl Med Assoc 1978; 70:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/27\">",
"      Ebling FJ. Apocrine glands in health and disorder. Int J Dermatol 1989; 28:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/28\">",
"      Schlapbach C, H&auml;nni T, Yawalkar N, Hunger RE. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 2011; 65:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/29\">",
"      Gniadecki R, Jemec GB. Lipid raft-enriched stem cell-like keratinocytes in the epidermis, hair follicles and sinus tracts in hidradenitis suppurativa. Exp Dermatol 2004; 13:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/30\">",
"      Danby FW, Margesson LJ. Hidradenitis suppurativa. Dermatol Clin 2010; 28:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/31\">",
"      Lapins J, Jarstrand C, Emtestam L. Coagulase-negative staphylococci are the most common bacteria found in cultures from the deep portions of hidradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999; 140:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/32\">",
"      Slade DE, Powell BW, Mortimer PS. Hidradenitis suppurativa: pathogenesis and management. Br J Plast Surg 2003; 56:451.",
"     </a>",
"    </li>",
"    <li>",
"     Revuz J. Hidradenitis suppurativa- patients' frequently asked questions. In: Hidradenitis suppurativa, Jemecs GBE, Revuz J, Leyden JJ (Eds), Heidelberg, Germany 2006. p.191.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/34\">",
"      Canoui-Poitrine F, Revuz JE, Wolkenstein P, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009; 61:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/35\">",
"      Stellon AJ, Wakeling M. Hidradenitis suppurativa associated with use of oral contraceptives. BMJ 1989; 298:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/36\">",
"      Lewis F, Messenger AG, Wales JK. Hidradenitis suppurativa as a presenting feature of premature adrenarche. Br J Dermatol 1993; 129:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/37\">",
"      Barth JH, Layton AM, Cunliffe WJ. Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa. Br J Dermatol 1996; 134:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/38\">",
"      Mortimer PS, Dawber RP, Gales MA, Moore RA. Mediation of hidradenitis suppurativa by androgens. Br Med J (Clin Res Ed) 1986; 292:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/39\">",
"      Harrison BJ, Read GF, Hughes LE. Endocrine basis for the clinical presentation of hidradenitis suppurativa. Br J Surg 1988; 75:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/40\">",
"      Judd HL, Yen SS. Serum androstenedione and testosterone levels during the menstrual cycle. J Clin Endocrinol Metab 1973; 36:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/41\">",
"      Camisa C, Sexton C, Friedman C. Treatment of hidradenitis suppurativa with combination hypothalamic-pituitary-ovarian and adrenal suppression. A case report. J Reprod Med 1989; 34:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/42\">",
"      Joseph MA, Jayaseelan E, Ganapathi B, Stephen J. Hidradenitis suppurativa treated with finasteride. J Dermatolog Treat 2005; 16:75.",
"     </a>",
"    </li>",
"    <li>",
"     Faure M. Endocrinology. In: Hidradenitis suppurativa, Jemec GBE, Revuz J, Leyden JJ (Eds), Heidelberg, Germany 2006. p.97.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/44\">",
"      Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol 2002; 119:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/45\">",
"      Chalmers RJ, Ead RD, Beck MH, et al. Acne vulgaris and hidradenitis suppurativa as presenting features of acromegaly. Br Med J (Clin Res Ed) 1983; 287:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/46\">",
"      Fitzsimmons JS, Fitzsimmons EM, Gilbert G. Familial hidradenitis suppurativa: evidence in favour of single gene transmission. J Med Genet 1984; 21:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/47\">",
"      Fitzsimmons JS, Guilbert PR. A family study of hidradenitis suppurativa. J Med Genet 1985; 22:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/48\">",
"      Fitzsimmons JS, Guilbert PR, Fitzsimmons EM. Evidence of genetic factors in hidradenitis suppurativa. Br J Dermatol 1985; 113:1.",
"     </a>",
"    </li>",
"    <li>",
"     Von der Werth J, Wood P, Irvine AD, Mclean WHI. Genetics of hidradenitis suppurativa. In: Hidradenitis suppurativa, Jemecs GBE, Revuz J, Leyden JJ (Eds), Heidelberg, Germany 2006. p.83.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/50\">",
"      Al-Ali FM, Ratnamala U, Mehta TY, et al. Hidradenitis suppurativa (or Acne inversa) with autosomal dominant inheritance is not linked to chromosome 1p21.1-1q25.3 region. Exp Dermatol 2010; 19:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/51\">",
"      Jemec GB. Hidradenitis suppurativa. J Cutan Med Surg 2003; 7:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/52\">",
"      Dvorak VC, Root RK, MacGregor RR. Host-defense mechanisms in hidradenitis suppurativa. Arch Dermatol 1977; 113:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/53\">",
"      O'Loughlin S, Woods R, Kirke PN, et al. Hidradenitis suppurativa. Glucose tolerance, clinical, microbiologic, and immunologic features and HLA frequencies in 27 patients. Arch Dermatol 1988; 124:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/54\">",
"      McDaniel DH, Welton WA. Furunculosis and hidradenitis suppurativa response. Arch Dermatol 1984; 120:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/55\">",
"      Ginder PA, Ousley M, Hinthorn D, et al. Hidradenitis suppurativa: evidence for a bactericidal defect correctable by cholinergic agonist in vitro and in vivo. J Clin Immunol 1982; 2:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/56\">",
"      Calprotectin, zinc, and abscesses. Lancet 1991; 338:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/57\">",
"      Anderson DK, Perry AW. Axillary hidradenitis. Arch Surg 1975; 110:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/58\">",
"      Williams ST, Busby RC, DeMuth RJ, Nelson H. Perineal hidradenitis suppurativa: presentation of two unusual complications and a review. Ann Plast Surg 1991; 26:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/59\">",
"      Silverberg B, Smoot CE, Landa SJ, Parsons RW. Hidradenitis suppurativa: patient satisfaction with wound healing by secondary intention. Plast Reconstr Surg 1987; 79:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/60\">",
"      Jemec GB. Hidradenitis suppurativa. Plast Reconstr Surg 1987; 80:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/61\">",
"      K&ouml;nig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999; 198:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/62\">",
"      CORNBLEET T. Pregnancy and apocrine gland diseases: hidradenitis, Fox-Fordyce disease. AMA Arch Derm Syphilol 1952; 65:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/63\">",
"      Roy MK, Appleton MA, Delicata RJ, et al. Probable association between hidradenitis suppurativa and Crohn's disease: significance of epithelioid granuloma. Br J Surg 1997; 84:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/64\">",
"      Person JR, Bernhard JD. Autointoxication revisited. J Am Acad Dermatol 1986; 15:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/65\">",
"      DONSKY HJ, MENDELSON CG. SQUAMOUS CELL CARCINOMA AS A COMPLICATION OF HIDRADENITIS SUPPURATIVA. Arch Dermatol 1964; 90:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/66\">",
"      Anstey AV, Wilkinson JD, Lord P. Squamous cell carcinoma complicating hidradenitis suppurativa. Br J Dermatol 1990; 123:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/67\">",
"      Mendon&ccedil;a H, Rebelo C, Fernandes A, et al. Squamous cell carcinoma arising in hidradenitis suppurativa. J Dermatol Surg Oncol 1991; 17:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/68\">",
"      Zachary LS, Robson MC, Rachmaninoff N. Squamous cell carcinoma occurring in hidradenitis suppurativa. Ann Plast Surg 1987; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     Mortimer PS. Hidradenitis suppurativa-diagnostic criteria. Acne and Related Disorders, 1st ed, Marks R, Plewig G (Eds), Martin Dunitz Ltd, London 1989. p.359.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/70\">",
"      Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/71\">",
"      Sartorius K, Emtestam L, Jemec GB, Lapins J. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity. Br J Dermatol 2009; 161:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/72\">",
"      Hana A, Booken D, Henrich C, et al. Functional significance of non-neuronal acetylcholine in skin epithelia. Life Sci 2007; 80:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/73\">",
"      Gupta AK, Knowles SR, Gupta MA, et al. Lithium therapy associated with hidradenitis suppurativa: case report and a review of the dermatologic side effects of lithium. J Am Acad Dermatol 1995; 32:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/74\">",
"      von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000; 14:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/75\">",
"      Smith HS, Chao JD, Teitelbaum J. Painful hidradenitis suppurativa. Clin J Pain 2010; 26:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/76\">",
"      Kurek A, Peters EM, Chanwangpong A, et al. Profound disturbances of sexual health in patients with acne inversa. J Am Acad Dermatol 2012; 67:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/77\">",
"      Wolkenstein P, Loundou A, Barrau K, et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007; 56:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/78\">",
"      van der Zee HH, van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Br J Dermatol 2010; 162:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/79\">",
"      Sahin MT, Ozt&uuml;rkcan S, T&uuml;rel-Ermertcan A, et al. Beh&ccedil;et's disease associated with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2007; 21:428.",
"     </a>",
"    </li>",
"    <li>",
"     Poli F, Jemec GBE, Revuz J. Clinical presentation. In: Hidradenitis suppurativa, Jemecs GBE, Revuz J, Leyden JJ (Eds), Heidelberg, Germany 2006. p.12-15.",
"    </li>",
"    <li>",
"     Kibbi, AG, El-Shareef, M. Granuloma inguinale. In: Fitzpatrick's Dermatology in General Medicine, 7th ed, Wolff, K, Goldsmith, LA, Katz, SI, et al. (Eds), McGraw Hill, 2008. p.1990.",
"    </li>",
"    <li>",
"     Hurley, HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Dermatologic surgery, Roenigk, RK, Roenigk, HH, (Eds) (Eds), New York 1989. p.729.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/83\">",
"      Bhalla R, Sequeira W. Arthritis associated with hidradenitis suppurativa. Ann Rheum Dis 1994; 53:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/84\">",
"      Lavogiez C, Delaporte E, Darras-Vercambre S, et al. Clinicopathological study of 13 cases of squamous cell carcinoma complicating hidradenitis suppurativa. Dermatology 2010; 220:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6265/abstract/85\">",
"      Fimmel S, Zouboulis CC. Comorbidities of hidradenitis suppurativa (acne inversa). Dermatoendocrinol 2010; 2:9.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5575 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6265=[""].join("\n");
var outline_f6_7_6265=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Predisposing factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Individual lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Primary (early) lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Secondary lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Tertiary lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Comedones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Follicular pyodermas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Granuloma inguinale",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Acne",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      HURLEY'S CLINICAL STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2318475\">",
"      ASSOCIATED CONDITIONS AND COMORBIDITIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/5575\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5575|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/25/38289\" title=\"picture 1\">",
"      Hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/3/34867\" title=\"picture 2A\">",
"      Moderate hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/14/42212\" title=\"picture 2B\">",
"      Severe hidradenitis suppurativa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/12/6338\" title=\"picture 3\">",
"      HS abscess",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/6/36975\" title=\"picture 4\">",
"      HS sinus1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/51/40755\" title=\"picture 5\">",
"      HS granuloma inguinale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/62/14310\" title=\"picture 6A\">",
"      HS Crohns1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?11/8/11395\" title=\"picture 6B\">",
"      HS Crohns2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/5575|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/55/31611\" title=\"table 1\">",
"      Hidradenitis suppurativa - associated disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/298?source=related_link\">",
"      Clinical manifestations and diagnosis of Beh&ccedil;et&rsquo;s disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/0/20490?source=related_link\">",
"      Clinical manifestations, diagnosis and prognosis of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/47/38649?source=related_link\">",
"      Dietary carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/23/22897?source=related_link\">",
"      Patient information: Hidradenitis suppurativa (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25273?source=related_link\">",
"      Perianal complications of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/44/24266?source=related_link\">",
"      Treatment of hidradenitis suppurativa",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_7_6266="Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation";
var content_f6_7_6266=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/7/6266/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6266/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6266/contributors\">",
"     Emilio Ramos, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/7/6266/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6266/contributors\">",
"     Barbara Murphy, MB, BAO, BCh, FRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/7/6266/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6266/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/7/6266/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/7/6266/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polyomaviruses are small DNA viruses that infect a variety of animals including monkeys, humans, rabbits, rodents, and birds, but tend to be species-specific [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The human polyomaviruses, such as the BK and JC virus are highly seroprevalent in humans but appear to cause clinical disease only in immunocompromised patients. BK virus primarily causes tubulointerstitial nephritis and ureteral stenosis in renal transplant recipients and hemorrhagic cystitis in bone marrow transplant recipients.",
"   </p>",
"   <p>",
"    Although the JC virus may also cause a nephropathy among renal transplant recipients, though perhaps with more inflammation and focal fibrosis, this is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. In this topic review, polyoma virus-induced nephropathy refers to BK-induced nephritis or nephropathy.",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of BK-induced nephritis in kidney transplant recipients will be presented here. BK-associated ureteral stenosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23843?source=see_link\">",
"     \"Ureteral stenosis due to BK virus infection among kidney transplant recipients\"",
"    </a>",
"    .) The treatment and general overviews of BK and other polyoma viruses are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1734?source=see_link\">",
"     \"Epidemiology of JC and BK virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The polyomaviruses are small (30 to 45 nm), icosahedral, nonenveloped, double-stranded, circular DNA viruses that are ubiquitous to humans, occurring with a seroprevalence of 60 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/7-13\">",
"     7-13",
"    </a>",
"    ]. BK and JC viruses encode six viral proteins. These are divided into two \"early\" nonstructural or enzymatic proteins, an agnoprotein, and three \"late\" proteins. The early proteins are the large tumor antigen, or \"T antigen,\" and the small tumor antigen, or the \"t antigen.\" The T antigen is responsible for cell immortalization and latency. The agnogene, which transcribes the agnoprotein, appears to participate in the assembly of viral particles. The \"late\" genes encode three viral capsid proteins: VP-1, VP-2, and VP-3.",
"   </p>",
"   <p>",
"    BK virus has been divided into four serological groups (I-IV) and genotypes, which may have different strengths of virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary infections tend to occur early in childhood via oral",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/15\">",
"     15",
"    </a>",
"    ]. Although these infections are innocuous, the virus remains latent in the renal epithelium (transitional epithelium, renal tubular epithelium, and parietal epithelium of Bowman's capsule) and lymphoid cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/10,16\">",
"     10,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intermittent active replication and asymptomatic viral shedding occurs in immunocompetent individuals (up to 20 percent incidence of shedding). By comparison, viral shedding is more common in immunocompromised patients (10 to 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/7,10,11,17-19\">",
"     7,10,11,17-19",
"    </a>",
"    ]. Patients with impaired cell-mediated immunity appear to be particularly vulnerable, including pregnant women (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/20\">",
"     20",
"    </a>",
"    ]. Viral shedding, however, disappears two weeks post partum.",
"   </p>",
"   <p>",
"    BK virus causes clinical disease of the genitourinary tract, due in part to its tropism for genitourinary epithelium. The primary location of the active replication may determine whether asymptomatic infection or disease occurs. The ability to replicate in blood or tissue may be due to genetic changes in the virus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. As an example, in one study, a 20-fold higher plasma viral BK load was associated with the identification of gene rearrangements of noncoding control regions from BK virus isolated from plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among transplant recipients, the intensity of immune suppression rather than the specific immunosuppressive agent used underlies the inability to control BK viral infection. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among kidney transplant recipients, BK virus primarily causes tubulointerstitial nephritis and ureteral stenosis. The reported estimated prevalence of BK-induced nephritis is 1 to 10 percent, with a mean of approximately 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/24-29\">",
"     24-29",
"    </a>",
"    ]. Ureteral stenosis is less common among transplant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23843?source=see_link&amp;anchor=H2#H2\">",
"     \"Ureteral stenosis due to BK virus infection among kidney transplant recipients\", section on 'Epidemiology'",
"    </a>",
"    .) BK-associated hemorrhagic or non-hemorrhagic cystitis occurs in bone marrow transplant recipients but is rarely observed among kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/8,9,17,31\">",
"     8,9,17,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The degree of immunosuppression is probably the most important risk factor underlying BK viral infection and some consider BK replication to be a reliable marker of excess immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/32\">",
"     32",
"    </a>",
"    ]. Although different drugs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    drug combinations have been associated with BK nephropathy (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the combined use of tacrolimus and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil) in various reports, no specific immunosuppressive drug or combination has been conclusively associated with BK nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/9,11,19,26,28,33-35\">",
"     9,11,19,26,28,33-35",
"    </a>",
"    ]. One prospective study, for example, found that the incidence of BK viruria and viremia were similar in patients randomly assigned to tacrolimus or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/36\">",
"     36",
"    </a>",
"    ]. BK virus nephropathy has also occurred in recipients receiving different combinations of cyclosporine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    as well as calcineurin inhibitor-free regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/37-41\">",
"     37-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although not universally accepted, other factors that have been associated with an increased risk of BK nephropathy include older and younger age, male gender, ureteral trauma, diabetes mellitus, delayed graft function (DGF) in renal transplant patients, cytomegalovirus infection, treatment for acute rejection, and white ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/26,28,42-44\">",
"     26,28,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BK viruria and viremia, which precede BK nephropathy, have been associated with high BK antibody titers in donors and negative or low BK antibody titers in recipients. BK viruria and viremia may be associated with specific HLA-C loci [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    BK nephropathy may be higher among HLA and ABO mismatched patients, possibly due to the increased rate of rejection and increased immunosuppression among such patients. This effect of HLA mismatching was shown in a study of 444 transplant recipients in which BK nephropathy was associated with HLA mismatching, the number of rejection episodes and a higher incidence of steroid-resistant rejection that required antilymphocyte treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/46\">",
"     46",
"    </a>",
"    ]. There was no specific HLA allele that was associated with BK nephropathy. Factors other than increased rate of rejection and increased immunosuppression may contribute to the enhanced risk however, since the risk among ABO-incompatible patients appears to be higher than that among HLA-mismatched patients. This was demonstrated in a study of 62 ABO-incompatible and 221 HLA-incompatible kidney transplant recipients of whom 17.7 versus 5.9 percent developed BK nephropathy, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/44\">",
"     44",
"    </a>",
"    ]. Even after controlling for the number of rejection episodes, ABO-incompatibility was an independent predictor of BK nephropathy. The risk of BK viremia is not known in this study.",
"   </p>",
"   <p>",
"    Rejection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ischemia of the transplanted kidney may increase the risk of BK nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/47\">",
"     47",
"    </a>",
"    ]. This is suggested by the observation that BK nephropathy rarely occurs in the native kidneys of patients who undergo non-renal solid organ transplantation, despite immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Viral-related factors such as polymorphisms within the VP1 and noncoding control region have been suggested to be risk factors by some [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/21-23\">",
"     21-23",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/50\">",
"     50",
"    </a>",
"    ] studies. One study failed to find the emergence of significant mutations or deletions in the noncoding control region as patients progressed from BK viruria to sustained BK viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/51\">",
"     51",
"    </a>",
"    ]. In this study, the antimetabolite was withdrawn in patients who had BK viremia which prevented progression to BK nephropathy. The authors surmised that withdrawing the antimetabolite may have removed the selective pressure to allow emergence of rearrangements in the noncoding control region that were associated with higher viral replication rates and nephropathy seen in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infection with other polyoma viruses, such as the JC virus, appears to decrease the risk of BK viral infection. This was demonstrated in a study of 200 renal transplant recipients in which patients with JC viruria were much less likely to have BK viruria [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among kidney transplant recipients, BK virus causes tubulointerstitial nephritis and rarely ureteral stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/30\">",
"     30",
"    </a>",
"    ]. Hemorrhagic and non-hemorrhagic cystitis may occur in bone marrow transplant recipients but is rarely observed among kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/8,9,17,31\">",
"     8,9,17,31",
"    </a>",
"    ]. Other even less common manifestations that have been associated with BK virus including vasculopathy, meningoencephalopathy, retinitis, pneumonitis, hepatitis, systemic lupus erythematosus, Guillain-Barr&eacute; syndrome, and a variety of neoplasms are discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222208\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with BK-associated interstitial nephritis most commonly present with an asymptomatic acute or slowly progressive rise in the serum creatinine concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Hematuria may be present. The onset of the disease occurs at a mean period of 10 to 13 months posttransplantation. However, the onset of nephritis may occur as early as six days posttransplantation or as late as five years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/8,18,41,56\">",
"     8,18,41,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H222485\">",
"    <span class=\"h2\">",
"     Laboratory and radiographic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with BK-induced interstitial nephritis, laboratory evaluation usually reveals an elevated serum creatinine. Routine urinalysis most commonly reveals pyuria, hematuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cellular casts consisting of renal tubular cells and inflammatory cells, findings consistent with interstitial nephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=see_link\">",
"     \"Urinalysis in the diagnosis of kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216527870\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A definitive diagnosis of BK nephritis is made by analysis of tissue obtained by renal biopsy. However, the diagnosis may be missed on biopsy since definitive lesions are focal in nature. A presumptive diagnosis may be made by PCR demonstration of BK replication in plasma in the absence or presence of kidney dysfunction. (See",
"    <a class=\"local\" href=\"#H1216526726\">",
"     'Polymerase chain reaction (PCR)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    BK-induced nephritis is first suspected clinically in the patient with clinical findings suggestive of interstitial nephritis. In our experience, there are",
"    <strong>",
"     NO",
"    </strong>",
"    clinical features of tubulointerstitial nephritis that are unique to BK virus infection.",
"   </p>",
"   <p>",
"    The suspicion of the diagnosis is supported by the identification of decoy cells on analysis of urine cytology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by quantitative PCR of urine",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plasma. (See",
"    <a class=\"local\" href=\"#H1216526719\">",
"     'Urine cytology'",
"    </a>",
"    below.) The sensitivity and specificity of the PCR appears to be institution dependent and must be interpreted in light of the clinical setting.",
"   </p>",
"   <p>",
"    The approach to the evaluation of patients with suspected BK nephritis varies by institution and their surveillance protocols. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One approach is to initiate the analysis with urine PCR. If the urine is positive (DNA PCR load &gt;10(7)",
"      <span class=\"nowrap\">",
"       copies/mL),",
"      </span>",
"      then plasma PCR is performed. If BK viremia (DNA PCR load &gt;10(4)",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      is found, an allograft biopsy is obtained.",
"     </li>",
"     <li>",
"      One approach is to screen using plasma PCR, with a positive result defined as a plasma DNA PCR load &gt;10(4)",
"      <span class=\"nowrap\">",
"       copies/mL.",
"      </span>",
"      In this setting, a biopsy is performed if there is concurrent evidence of allograft dysfunction.",
"     </li>",
"     <li>",
"      Another approach is to screen first using urine cytology. If present on two successive occasions over four weeks,",
"      <span class=\"nowrap\">",
"       and/",
"      </span>",
"      or plasma PCR is positive (DNA PCR load &gt;10(4)",
"      <sup>",
"       <span class=\"nowrap\">",
"       </span>",
"      </sup>",
"      copies/mL),",
"      an allograft biopsy is obtained regardless of renal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of the evaluation process in institutions that use a screening and preemptive strategy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\", section on 'Screening and preemptive strategy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A definitive diagnosis of BK-induced nephritis requires the following findings on renal biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/26,57,58\">",
"     26,57,58",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Characteristic cytopathic changes. (See",
"      <a class=\"local\" href=\"#H1216526833\">",
"       'Histology'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     PLUS",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Positive immunohistochemistry tests using antibodies directed specifically against BK or against the cross-reacting SV40 large-T antigen. Positive SV40 staining is pathognomonic, as it is associated with a specificity of almost 100 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of the focal nature of early BK nephropathy, the diagnosis may be missed on one-third of biopsies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/57,59\">",
"     57,59",
"    </a>",
"    ]. As a result, at least two biopsy cores, preferably including medulla, should be examined [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/60\">",
"     60",
"    </a>",
"    ]. Medullary tissue should be included because the virus is more likely to be present in the medulla. If the initial biopsy does not confirm BK, a repeat biopsy should be considered.",
"   </p>",
"   <p>",
"    A presumptive diagnosis of BK nephropathy may be made in the absence of definitive findings on biopsy. Findings of sustained (more than two weeks duration) urinary viral shedding and significant BK replication (plasma DNA PCR load &gt;10,000",
"    <span class=\"nowrap\">",
"     copies/mL)",
"    </span>",
"    with or without kidney dysfunction defines presumptive BK nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/26,57\">",
"     26,57",
"    </a>",
"    ]. The management of BK nephropathy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\", section on 'Screening and preemptive strategy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216526719\">",
"    <span class=\"h2\">",
"     Urine cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytologic examination of urine may reveal BK-infected cells. The most characteristic abnormality of infected cells is an enlarged nucleus with a single large basophilic intranuclear inclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. The presence of characteristic cytopathologic changes in infected cells (which have been called decoy cells due to their resemblance to renal carcinoma cells) is strongly suggestive of polyomavirus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/24,56\">",
"     24,56",
"    </a>",
"    ]. As noted above, viral replication in the urine demonstrated by either urine decoy cells or urine qualitative PCR is found in 20 to 60 percent of patients, depending on the method of detection, and precedes BK viremia by a median of four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, decoy cells are not entirely sensitive or specific for BK virus infection:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They can be confused with those due to other viruses, such as adenovirus and cytomegalovirus (CMV) infection, although the cytomegalovirus causes cytoplasmic rather than intranuclear inclusions [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"       \"Diagnosis of cytomegalovirus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They do not necessarily correlate with biopsy-verified BK-induced interstitial nephritis in renal transplant recipients. A specificity of 71 percent for decoy cells was noted in a prospective report of 78 renal transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/24\">",
"       24",
"      </a>",
"      ]. Another study found a strong correlation between nephritis and an increased number of polyomavirus infected cells",
"      <span class=\"nowrap\">",
"       (&gt;10/cytospin)",
"      </span>",
"      in combination with an inflammatory urinalysis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/10\">",
"       10",
"      </a>",
"      ]. In this study, urinalyses revealing cellular casts consisting of renal tubular cells (with nuclei showing features of polyomavirus infection) and inflammatory cells were observed in seven of eight patients with biopsy-confirmed BK-induced nephritis.",
"     </li>",
"     <li>",
"      Cytologic abnormalities may be absent when other tests that directly detect BK virus in the urine are positive [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/63-65\">",
"       63-65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, urine cytology showing characteristic cytologic abnormalities is suggestive, but not definitive, for BK-induced interstitial nephritis. Their absence does not exclude the disease. The repeated presence of urinary decoy cells, however, is sensitive for the diagnosis of BK nephritis, although urine PCR is two to four times more sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H1216526726\">",
"     'Polymerase chain reaction (PCR)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216526726\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction (PCR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prolonged presence of increased viral DNA levels in the plasma of renal transplant recipients who have an appropriate clinical picture suggests BK-associated interstitial nephritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 78 renal transplant recipients, the presence of BK viral DNA as detected by polymerase chain reaction (PCR) was associated with a sensitivity and specificity of 100 and 88 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study, nine of nine transplant recipients with biopsy-proven polyomavirus type BK-associated nephropathy had BK viral DNA detected in plasma by PCR [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/11\">",
"       11",
"      </a>",
"      ]. By comparison, such DNA was found in only 2 of 41 recipients without nephropathy and in none of 17 nontransplant patients with advanced HIV-1 infection. Viral DNA disappeared with a decrease in immunosuppression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216526769\">",
"    <span class=\"h3\">",
"     Quantitative polymerase chain reaction (PCR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitative or real time PCR for BK viral DNA of plasma or serum and less so of urine appears to be useful in monitoring kidney transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/64,66\">",
"     64,66",
"    </a>",
"    ]. Prospective and retrospective studies have suggested that BK viral infections progress through detectable stages [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/64,66-68\">",
"     64,66-68",
"    </a>",
"    ]. Viral replication in the urine precedes BK viremia by approximately four weeks. Viral replication in the urine as detected by either the analysis of urine cytology or demonstration of virus by quantitative PCR has been shown to be present in 20 to 60 percent of renal transplant recipients, depending on the method of detection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/26\">",
"     26",
"    </a>",
"    ]. BK viremia is detected in 10 to 30 percent of recipients in the first six months post-transplantation, and in 5 to 10 percent of recipients thereafter. Histological changes of BK nephropathy are observed twelve weeks after BK viruria and are detected in approximately 2 to 10 percent of recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/26\">",
"     26",
"    </a>",
"    ]. (",
"    <a class=\"graphic graphic_figure graphicRef83389 \" href=\"UTD.htm?13/59/14256\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Renal transplant recipients with higher urine DNA levels are more likely to develop detectable DNA in plasma, and prolonged DNAemia precedes clinically-overt nephropathy. In one study, although the risks of viremia and sustained viremia were 3- and 13-fold higher if the urine DNA level was &gt;9.5 log10",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    the sensitivity, specificity, positive predictive value, and negative predictive values of urine levels were 70, 70, 53, and 83 percent for any viremia and 91, 66, 33, and 98 percent for sustained viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/36\">",
"     36",
"    </a>",
"    ]. Others have also found a correlation between negative PCR of urine and negative PCR of plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important to realize that DNA levels may vary by assay [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/19\">",
"     19",
"    </a>",
"    ], with variations of a magnitude of 1 to 2 log fold in sequential weekly analyses in a commercially available quantitative PCR assay. Therefore, when considering initiation or alteration of therapeutic options, the trend in quantitative DNA levels may be more important than a single value. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\", section on 'Screening and preemptive strategy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PCR may also distinguish BK from JC reactivation.",
"   </p>",
"   <p>",
"    PCR of biopsy tissue is not an appropriate test for the primary diagnosis of BK nephropathy, because it can detect latent virus even in asymptomatic individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/14,70\">",
"     14,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216526812\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum antibodies directed against the BK virus are common in the general population and are generally",
"    <strong>",
"     NOT",
"    </strong>",
"    helpful in the diagnosis of BK-virus infection affecting the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/9\">",
"     9",
"    </a>",
"    ]. Infection can be detected by a marked rise in serum BK IgG titers as early as six weeks and as late as two years post-primary infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. The rise in BK IgG may be higher when the donor is BK-virus antibody positive [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/9,16\">",
"     9,16",
"    </a>",
"    ]. A rise in serum antibody to BK virus, which does not appear to be protective, may also occur due to reactivation of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/45\">",
"     45",
"    </a>",
"    ]. Recipient seropositivity may ameliorate the disease and prevent progression of the infection from transient viruria to sustained viremia, which, as discussed above, is considered a harbinger of BK nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/67,71\">",
"     67,71",
"    </a>",
"    ]. The type of antibody response, IgG, IgM, or IgA, may also be used to determine the intensity of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of checking pretransplant BK antibody serostatus is not clear. Although a positive donor serostatus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/16,72\">",
"     16,72",
"    </a>",
"    ] and negative recipient serostatus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/73,74\">",
"     73,74",
"    </a>",
"    ] have been implicated as risk factors for BK infection in renal transplant recipients, the donor seropositive and recipient seronegative combination has not been identified as a risk factor for the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, donor seropositivity has been implicated in the development of recipient BK viruria, viremia, and sustained viremia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/45\">",
"     45",
"    </a>",
"    ]. Sustained viremia may lead to BK nephropathy if appropriate intervention is not undertaken, such as discontinuation of the antimetabolite component of the immunosuppressive regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216526819\">",
"    <span class=\"h2\">",
"     Virus culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;BK virus is likely to be isolated from urine prior to the detection of a rise in antibody titers, most often due to reactivation of latent BK virus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/9\">",
"     9",
"    </a>",
"    ]. However, virus culture is rarely used to detect virus infection outside of a research setting. These viruses grow slowly in tissue culture, and susceptible cell lines are not readily available. Isolation of these viruses from clinical specimens can require weeks to months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216526826\">",
"    <span class=\"h2\">",
"     Urine electron microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Negative staining electron microscopy of the urine of patients with BK nephropathy may reveal the presence of cast-like three-dimensional polyomavirus aggregates, termed Haufen [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/75\">",
"     75",
"    </a>",
"    ]. In a retrospective single-center study, the presence of such structures was associated with a sensitivity and specificity for biopsy-verified BK nephropathy of 100 and 99 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The utility of this diagnostic technique remains to be determined. It requires sophisticated analysis and interpretation from pathologists. Its greatest utility is to differentiate symptomatic from asymptomatic BK viral replication.",
"   </p>",
"   <p>",
"    Additionally, whether urine electron microscopy can discriminate between rejection and BK nephropathy was not determined by the study cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/75\">",
"     75",
"    </a>",
"    ]. Despite these limitations, a high Haufen load suggests that, among those with an equivocal biopsy, BK nephropathy is the cause of the allograft dysfunction and not rejection; thus, reduction rather than augmentation of the immunosuppressive regimen is warranted. Prospective studies in additional centers must be performed to better understand the role, if any, of this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216526833\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;BK virus nephropathy is associated with characteristic histologic findings on kidney biopsy. Since they also can be observed with CMV, adenovirus, and human herpes simplex virus (HHSV) infections, many of the morphologic changes are not pathognomonic. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intranuclear basophilic viral inclusions without a surrounding halo [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/8,10,18,25\">",
"       8,10,18,25",
"      </a>",
"      ]. CMV has cytoplasmic inclusions, as noted above, and HHSV has both intranuclear and cytoplasmic inclusions.",
"     </li>",
"     <li>",
"      Anisonucleosis, hyperchromasia, and chromatin clumping of infected cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/10,18,25\">",
"       10,18,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interstitial mononuclear or polymorphonuclear cell infiltrates in the areas of tubular damage [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/10,18,25\">",
"       10,18,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tubular injury, which is characterized by tubular cell apoptosis, cell drop out, desquamation, and flattened epithelial lining [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/10,18,25\">",
"       10,18,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tubulitis, which is manifested by lymphocyte permeation of the tubular basement membrane. When extensive, it is difficult to differentiate BK nephritis from allograft rejection [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/8,10,18,25\">",
"       8,10,18,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With electron microscopy, intranuclear viral inclusions (with a diameter size of 30 to 50 nm) and tubular damage characterized by tubular cell necrosis, prominent lysosomal inclusions, and luminal protein and cellular casts [",
"      <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/8,10,18,25\">",
"       8,10,18,25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three patterns have been proposed to describe the histologic findings in patients with BK-induced nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/59,76\">",
"     59,76",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pattern A:",
"      <span class=\"nowrap\">",
"       Cytopathic/cytolytic",
"      </span>",
"      changes with absent or minimal inflammation",
"     </li>",
"     <li>",
"      Pattern B:",
"      <span class=\"nowrap\">",
"       Cytopathic/cytolytic",
"      </span>",
"      changes associated with patchy or diffuse tubulointerstitial inflammation and atrophy",
"     </li>",
"     <li>",
"      Pattern C: Graft sclerosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histologic appearance is often similar to cellular rejection. It is important to distinguish BK nephritis from rejection since the treatment of presumed rejection with increased immunosuppression may result in allograft loss if BK nephritis is present. BK nephritis is generally distinguished from rejection by the presence of BK virus inclusions and immunohistologic or in situ hybridization evidence of virally infected cells. BK virus usually infects tubular epithelial cells, although a single case of fatal BK-related vasculopathy has been reported, in which endothelial cells but not tubular epithelial cells showed immunoreactivity to BK virus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/77\">",
"     77",
"    </a>",
"    ]. Correlation of histologic findings with BK viremia is essential among patients with ambiguous histologic features.",
"   </p>",
"   <p>",
"    In addition, BK nephritis may co-exist with acute rejection, although this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/25,78,79\">",
"     25,78,79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H17\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allograft rejection is the principal disorder that most closely resembles BK-induced interstitial nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/8,15,54-56\">",
"     8,15,54-56",
"    </a>",
"    ]. As noted above, distinguishing BK nephritis from allograft rejection is exceedingly important since treatment for presumed rejection with increased immunosuppression may result in allograft loss.",
"   </p>",
"   <p>",
"    As noted above, BK-induced nephritis may be distinguished from allograft rejection by the presence of BK virus inclusions and immunohistologic or in situ hybridization evidence of virally infected cells, which are usually tubular epithelial cells, rather than podocytes or endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/25\">",
"     25",
"    </a>",
"    ]. It is important to correlate the histologic findings with PCR evidence of viremia.",
"   </p>",
"   <p>",
"    A separate issue is identifying co-existing lesions of BK nephritis and acute rejection. Whether BK nephropathy and cellular, humoral, or mixed rejection can exist concomitantly is controversial. One group reported that 13 of 24 (54 percent) biopsies obtained during persistent BK-nephropathy met traditional histological criteria for acute rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/25\">",
"     25",
"    </a>",
"    ]. However, a causal association between BK nephropathy and rejection was not shown in this study. In particular, only the patients with histologic evidence of rejection had increased tubular epithelial cell HLA and ICAM expression, suggesting the BK virus does not provoke rejection by inducing inflammation. By contrast, another study demonstrated increased expression of HLA-DR among patients with BK nephropathy, and the transcriptional profiles of BK-nephropathy and acute rejection were remarkably similar [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/80\">",
"     80",
"    </a>",
"    ]. In this study, the expression of genes associated with inflammation and acute rejection (such as CD8, interferon-gamma, CXCR3, and perforin) was higher in patients with BK-nephropathy compared with acute rejection. Compared with rejection, BK nephropathy was associated with increased expression of transcription molecules associated with graft fibrosis including matrix collagens, TGF beta, MMP2 and 9. There is only report of a patient with simultaneous BK nephropathy and antibody mediated rejection characterized by diffuse C4d staining and donor specific antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of whether BK nephritis and rejection are causally or coincidentally associated, it is important to identify both lesions. This can be difficult, especially among patients who have sparse viral cytopathic changes or who had biopsies performed after immunosuppression had already been reduced. Establishing the diagnosis requires an experienced pathologist who is familiar with BK activation.",
"   </p>",
"   <p>",
"    In general, the presence of extensive tubulitis in areas remote from the viral cytopathic changes suggests acute rejection is present in addition to BK nephritis. The combined presence of endarteritis, fibrinoid vascular necrosis, glomerulitis, and C4d deposits along peritubular capillaries is conclusive evidence of concurrent rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/26\">",
"     26",
"    </a>",
"    ], although some patients with BK nephropathy without concurrent rejection may have C4D deposits in the tubular basement membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?6/7/6266/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among some patients, it may only be possible to distinguish the effects of BK viral infection from those of rejection by empirically altering the immunosuppressive regimen and observing the clinical response. The most commonly accepted strategy is to lower immunosuppression even when there is histological evidence of rejection. Others use a short course of steroids (such as pulse intravenous solumedrol for three days followed by taper) in order to decrease inflammation and then reduce the immunosuppression or administer intravenous immunoglobulin for its immunomodulatory and possible anti-BK effects.",
"   </p>",
"   <p>",
"    The differential diagnosis also includes many disorders associated with early (1 to 12 weeks posttransplantation) and late (more than three months posttransplantation) renal allograft dysfunction. These are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=see_link\">",
"     \"Differential diagnosis of renal allograft dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute renal allograft rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among renal transplant recipients, the major diseases caused by BK virus include tubulointerstitial nephritis and ureteral stenosis. The prevalence of BK-induced nephritis in kidney transplant recipients is estimated to be 1 to 10 percent, with a mean of approximately 5 percent. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among renal transplant recipients, the incidence of BK viral infection directly correlates with the degree of immunosuppression although no specific immunosuppressive drug or combination has been associated with BK nephropathy. Other potential risk factors include older and younger age, male gender, ureteral trauma, diabetes mellitus, delayed graft function, cytomegalovirus infection, treatment for acute rejection, and white ethnicity. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Quantitative or real time polymerase chain reaction (PCR) for BK viral DNA of plasma or serum and less so of urine appears to be useful in monitoring kidney transplant recipients for BK infection. BK viral infections progress through detectable stages. Viral replication in the urine precedes BK viremia by approximately four weeks. Histological changes of BK nephropathy are observed twelve weeks after BK viruria. Renal transplant recipients with higher urine DNA levels are more likely to develop detectable DNA in plasma, and prolonged DNAemia precedes clinically-overt nephropathy. (See",
"      <a class=\"local\" href=\"#H1216526726\">",
"       'Polymerase chain reaction (PCR)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1216526769\">",
"       'Quantitative polymerase chain reaction (PCR)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with BK-associated interstitial nephritis usually present with an asymptomatic acute or slowly progressive rise in the serum creatinine concentration. Urinalysis reveals pyuria, hematuria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cellular casts consisting of renal tubular cells and inflammatory cells. Urine cytologic examination may reveal BK-infected cells called decoy cells. A definitive diagnosis of BK nephropathy is made by renal allograft biopsy. The histologic diagnosis requires the presence of characteristic cytopathic changes and positive immunohistochemistry tests using antibodies directed specifically against BK or against the cross-reacting SV40 large-T antigen. Since BK-induced nephropathy may be missed on one-third of biopsies, at least two biopsy cores, preferably including medulla, should be examined. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of definitive histologic evidence obtained by biopsy, findings of sustained urine viral replication (more than two weeks duration) and significant BK replication (plasma DNA PCR load &gt;10,000",
"      <span class=\"nowrap\">",
"       copies/mL)",
"      </span>",
"      with or without kidney dysfunction defines presumptive BK nephropathy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The major differential diagnosis of BK-associated interstitial nephritis is acute rejection. As noted above, BK-induced nephritis may be distinguished from allograft rejection by the presence of BK virus inclusions and immunohistologic or in situ hybridization evidence of virally infected cells, which are usually tubular epithelial cells, rather than podocytes or endothelial cells. It is important to correlate the histologic findings with PCR evidence of viremia. (See",
"      <a class=\"local\" href=\"#H1216526833\">",
"       'Histology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The histological appearance of rejection may occur in more than 50 percent of patients with BK-nephropathy. In general, the presence of extensive tubulitis in areas remote from the viral cytopathic changes suggests acute rejection is present in addition to BK nephritis. The combined presence of endarteritis, fibrinoid vascular necrosis, glomerulitis, and C4d deposits along peritubular capillaries is conclusive evidence of concurrent rejection. Among some patients, it may only be possible to distinguish the effects of BK viral infection from those of rejection by empirically altering the immunosuppressive regimen and observing the clinical response. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Imperiale, M. The Human Polyomaviruses: An Overview. In: Human Polyomaviruses: Molecular and Clinical Perspectives, Khalili, K and Stoner, GL (Eds), Wiley-Liss, Wilmington, DE, 2001. p. 54.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/2\">",
"      Randhawa P, Baksh F, Aoki N, et al. JC virus infection in allograft kidneys: analysis by polymerase chain reaction and immunohistochemistry. Transplantation 2001; 71:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/3\">",
"      Drachenberg CB, Hirsch HH, Papadimitriou JC, et al. Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation. Transplantation 2007; 84:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/4\">",
"      Kazory A, Ducloux D, Chalopin JM, et al. The first case of JC virus allograft nephropathy. Transplantation 2003; 76:1653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/5\">",
"      Costa C, Bergallo M, Sidoti F, et al. Polyomaviruses BK- And JC-DNA quantitation in kidney allograft biopsies. J Clin Virol 2009; 44:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/6\">",
"      Ramos E, Drachenberg CB, Wali R, Hirsch HH. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 2009; 87:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/7\">",
"      Bratt G, Hammarin AL, Grandien M, et al. BK virus as the cause of meningoencephalitis, retinitis and nephritis in a patient with AIDS. AIDS 1999; 13:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/8\">",
"      Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/9\">",
"      Gardner SD, MacKenzie EF, Smith C, Porter AA. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol 1984; 37:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/10\">",
"      Drachenberg CB, Beskow CO, Cangro CB, et al. Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. Hum Pathol 1999; 30:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/11\">",
"      Nickeleit V, Klimkait T, Binet IF, et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/12\">",
"      Stoian M, Hozoc M, Iosipenco M, et al. Serum antibodies to papova viruses (BK and SV 40) in subjects from the area with Balkan endemic nephropathy. Virologie 1983; 34:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/13\">",
"      Hirsch HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal transplantation. Am J Transplant 2002; 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/14\">",
"      Baksh FK, Finkelstein SD, Swalsky PA, et al. Molecular genotyping of BK and JC viruses in human polyomavirus-associated interstitial nephritis after renal transplantation. Am J Kidney Dis 2001; 38:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/15\">",
"      Pahari A, Rees L. BK virus-associated renal problems--clinical implications. Pediatr Nephrol 2003; 18:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/16\">",
"      Shah KV. Human polyomavirus BKV and renal disease. Nephrol Dial Transplant 2000; 15:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/17\">",
"      Peinemann F, de Villiers EM, D&ouml;rries K, et al. Clinical course and treatment of haemorrhagic cystitis associated with BK type of human polyomavirus in nine paediatric recipients of allogeneic bone marrow transplants. Eur J Pediatr 2000; 159:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/18\">",
"      Howell DN, Smith SR, Butterly DW, et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999; 68:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/19\">",
"      Bressollette-Bodin C, Coste-Burel M, Hourmant M, et al. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant 2005; 5:1926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/20\">",
"      Coleman DV, Wolfendale MR, Daniel RA, et al. A prospective study of human polyomavirus infection in pregnancy. J Infect Dis 1980; 142:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/21\">",
"      Funk GA, Steiger J, Hirsch HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis 2006; 193:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/22\">",
"      Gosert R, Rinaldo CH, Funk GA, et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008; 205:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/23\">",
"      Olsen GH, Andresen PA, Hilmarsen HT, et al. Genetic variability in BK Virus regulatory regions in urine and kidney biopsies from renal-transplant patients. J Med Virol 2006; 78:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/24\">",
"      Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/25\">",
"      Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/26\">",
"      Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/27\">",
"      Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/28\">",
"      Schold JD, Rehman S, Kayle LK, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/29\">",
"      van Aalderen MC, Heutinck KM, Huisman C, ten Berge IJ. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med 2012; 70:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/30\">",
"      Gupta M, Miller F, Nord EP, Wadhwa NK. Delayed renal allograft dysfunction and cystitis associated with human polyomavirus (BK) infection in a renal transplant recipient: a case report and review of literature. Clin Nephrol 2003; 60:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/31\">",
"      Gardner SD, Field AM, Coleman DV, Hulme B. New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1971; 1:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/32\">",
"      Gralla J, Huskey J, Wiseman AC. Trends in immune function assay (ImmuKnow; Cylex&trade;) results in the first year post-transplant and relationship to BK virus infection. Nephrol Dial Transplant 2012; 27:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/33\">",
"      Fink, JC, Wiland, AM, Rochussen, JR, et al. The increased incidence of BK polyomavirus in renal transplant recipients treated with Prograf. Transplantation 2000; 69:S385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/34\">",
"      Mengel M, Marwedel M, Radermacher J, et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003; 18:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/35\">",
"      Dadhania D, Snopkowski C, Ding R, et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation 2008; 86:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/36\">",
"      Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/37\">",
"      GROSS L. A filterable agent, recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. Proc Soc Exp Biol Med 1953; 83:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/38\">",
"      Hirsch HH, Mohaupt M, Klimkait T. Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy. J Infect Dis 2001; 184:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/39\">",
"      Lipshutz GS, Flechner SM, Govani MV, Vincenti F. BK nephropathy in kidney transplant recipients treated with a calcineurin inhibitor-free immunosuppression regimen. Am J Transplant 2004; 4:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/40\">",
"      Lipshutz GS, Mahanty H, Feng S, et al. Polyomavirus-associated nephropathy in simultaneous kidney-pancreas transplant recipients: a single-center experience. Transplant Proc 2004; 36:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/41\">",
"      Sachdeva MS, Nada R, Jha V, et al. The high incidence of BK polyoma virus infection among renal transplant recipients in India. Transplantation 2004; 77:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/42\">",
"      Thomas A, Dropulic LK, Rahman MH, Geetha D. Ureteral stents: a novel risk factor for polyomavirus nephropathy. Transplantation 2007; 84:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/43\">",
"      Randhawa P, Ramos E. BK viral nephropathy: an overview. Transplantation Reviews 2007; 21:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/44\">",
"      Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol 2012; 7:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/45\">",
"      Bohl DL, Storch GA, Ryschkewitsch C, et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005; 5:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/46\">",
"      Awadalla Y, Randhawa P, Ruppert K, et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 2004; 4:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/47\">",
"      Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol 2007; 2 Suppl 1:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/48\">",
"      Limaye AP, Smith KD, Cook L, et al. Polyomavirus nephropathy in native kidneys of non-renal transplant recipients. Am J Transplant 2005; 5:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/49\">",
"      Barber CE, Hewlett TJ, Geldenhuys L, et al. BK virus nephropathy in a heart transplant recipient: case report and review of the literature. Transpl Infect Dis 2006; 8:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/50\">",
"      Boldorini R, Veggiani C, Turello E, et al. Are sequence variations in the BK virus control region essential for the development of polyomavirus nephropathy? Am J Clin Pathol 2005; 124:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/51\">",
"      Memon IA, Parikh BA, Gaudreault-Keener M, et al. Progression from Sustained BK Viruria to Sustained BK Viremia with Immunosuppression Reduction Is Not Associated with Changes in the Noncoding Control Region of the BK Virus Genome. J Transplantation 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/52\">",
"      Cheng XS, Bohl DL, Storch GA, et al. Inhibitory interactions between BK and JC virus among kidney transplant recipients. J Am Soc Nephrol 2011; 22:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/53\">",
"      Reploeg MD, Storch GA, Clifford DB. Bk virus: a clinical review. Clin Infect Dis 2001; 33:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/54\">",
"      Vasudev B, Hariharan S, Hussain SA, et al. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68:1834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/55\">",
"      Dall A, Hariharan S. BK virus nephritis after renal transplantation. Clin J Am Soc Nephrol 2008; 3 Suppl 2:S68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/56\">",
"      Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/57\">",
"      Drachenberg CB, Papadimitriou JC. Polyomavirus-associated nephropathy: update in diagnosis. Transpl Infect Dis 2006; 8:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/58\">",
"      Wiseman AC. Polyomavirus nephropathy: a current perspective and clinical considerations. Am J Kidney Dis 2009; 54:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/59\">",
"      Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004; 4:2082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/60\">",
"      The American Society of Transplantation Infectious Diseases Guidelines. Am J Transplant 2009; 9(Suppl 4):S92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/61\">",
"      Kahan AV, Coleman DV, Koss LG. Activation of human polyomavirus infection-detection by cytologic technics. Am J Clin Pathol 1980; 74:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/62\">",
"      Traystman MD, Gupta PK, Shah KV, et al. Identification of viruses in the urine of renal transplant recipients by cytomorphology. Acta Cytol 1980; 24:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/63\">",
"      Arthur RR, Shah KV. Occurrence and significance of papovaviruses BK and JC in the urine. Prog Med Virol 1989; 36:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/64\">",
"      Coleman DV, Gardner SD, Field AM. Human polyomavirus infection in renal allograft recipients. Br Med J 1973; 3:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/65\">",
"      Randhawa P, Vats A, Shapiro R. Monitoring for polyomavirus BK And JC in urine: comparison of quantitative polymerase chain reaction with urine cytology. Transplantation 2005; 79:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/66\">",
"      Agha, IA, Alvarez, A, Lopez, L, et al. Human polyoma virus infects a high proportion of renal allograft recipients and the incidence is not affected by choice of calcineurin inhibitor (abstract). J Am Soc Nephrol 2001; 12:A4577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/67\">",
"      Bohl DL, Brennan DC, Ryschkewitsch C, et al. BK virus antibody titers and intensity of infections after renal transplantation. J Clin Virol 2008; 43:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/68\">",
"      Saundh BK, Baker R, Harris M, et al. Early BK polyomavirus (BKV) reactivation in donor kidney is a risk factor for development of BKV-associated nephropathy. J Infect Dis 2013; 207:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/69\">",
"      Randhawa PS, Demetris AJ. Nephropathy due to polyomavirus type BK. N Engl J Med 2000; 342:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/70\">",
"      Schmid H, Nitschko H, Gerth J, et al. Polyomavirus DNA and RNA detection in renal allograft biopsies: results from a European multicenter study. Transplantation 2005; 80:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/71\">",
"      Randhawa P, Bohl D, Brennan D, et al. longitudinal analysis of levels of immunoglobulins against BK virus capsid proteins in kidney transplant recipients. Clin Vaccine Immunol 2008; 15:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/72\">",
"      Andrews CA, Shah KV, Daniel RW, et al. A serological investigation of BK virus and JC virus infections in recipients of renal allografts. J Infect Dis 1988; 158:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/73\">",
"      Smith JM, McDonald RA, Finn LS, et al. Polyomavirus nephropathy in pediatric kidney transplant recipients. Am J Transplant 2004; 4:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/74\">",
"      Ginevri F, De Santis R, Comoli P, et al. Polyomavirus BK infection in pediatric kidney-allograft recipients: a single-center analysis of incidence, risk factors, and novel therapeutic approaches. Transplantation 2003; 75:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/75\">",
"      Singh HK, Andreoni KA, Madden V, et al. Presence of urinary Haufen accurately predicts polyomavirus nephropathy. J Am Soc Nephrol 2009; 20:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/76\">",
"      Drachenberg RC, Drachenberg CB, Papadimitriou JC, et al. Morphological spectrum of polyoma virus disease in renal allografts: diagnostic accuracy of urine cytology. Am J Transplant 2001; 1:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/77\">",
"      Petrogiannis-Haliotis T, Sakoulas G, Kirby J, et al. BK-related polyomavirus vasculopathy in a renal-transplant recipient. N Engl J Med 2001; 345:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/78\">",
"      McGilvray ID, Lajoie G, Humar A, Cattral MS. Polyomavirus infection and acute vascular rejection in a kidney allograft: coincidence or mimicry? Am J Transplant 2003; 3:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/79\">",
"      Atsumi H, Asaka M, Kimura S, et al. A case of second renal transplantation with acute antibody-mediated rejection complicated with BK virus nephropathy. Clin Transplant 2010; 24 Suppl 22:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/80\">",
"      Mannon RB, Hoffmann SC, Kampen RL, et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant 2005; 5:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/7/6266/abstract/81\">",
"      Batal I, Zainah H, Stockhausen S, et al. The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy. Mod Pathol 2009; 22:1468.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7336 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6266=[""].join("\n");
var outline_f6_7_6266=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222208\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H222485\">",
"      Laboratory and radiographic findings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1216527870\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1216526719\">",
"      Urine cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1216526726\">",
"      Polymerase chain reaction (PCR)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1216526769\">",
"      - Quantitative polymerase chain reaction (PCR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1216526812\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1216526819\">",
"      Virus culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1216526826\">",
"      Urine electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1216526833\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7336\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7336|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/59/14256\" title=\"figure 1\">",
"      Course of BK-induced nephropathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/13/12505?source=related_link\">",
"      Clinical manifestations and diagnosis of acute renal allograft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/1/2072?source=related_link\">",
"      Differential diagnosis of renal allograft dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/44/1734?source=related_link\">",
"      Epidemiology of JC and BK virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/18/23843?source=related_link\">",
"      Ureteral stenosis due to BK virus infection among kidney transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/34/22058?source=related_link\">",
"      Urinalysis in the diagnosis of kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_7_6267="Causes of bloody stool appearance PI";
var content_f6_7_6267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F61276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F61276&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    List of foods and drugs that can make a child&rsquo;s bowel movements look bloody",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Red stools (which may look like fresh blood)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antibiotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span class=\"indent1\">",
"         Beets",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flavored gelatin (red colored)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kool-Aid&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red licorice&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Black stools (which may look like old blood)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stomach medicines that contain bismuth (like Pepto-Bismol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chocolate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Iron supplements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lots of dark green foods",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6267=[""].join("\n");
var outline_f6_7_6267=null;
var title_f6_7_6268="Diagnostic tests developmental coordination disorder";
var content_f6_7_6268=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of instruments used in the diagnosis of developmental coordination disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Movement Assessment Battery for Children (MABC)",
"        <sup>",
"         [1]",
"        </sup>",
"        or MABC, second edition (MABC2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gubbay screening&nbsp;test",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        McCarron Assessment of Neuromuscular Development",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bruininks-Oseretski Test of Motor Proficiency (BOTMP)",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Southern California Sensory Integration Tests",
"        <sup>",
"         [5,6]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beery-Buktenica Developmental Test of Visual-Motor Integration",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peabody Developmental Motor Scales",
"        <sup>",
"         [8]",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Hendersen SE, Sugden DA. Movement assessment battery for children. The Psychological Corporation 1992.",
"       </li>",
"       <li>",
"        Gubbay SS. The Clumsy Child, Saunders, Phildadelphia 1975.",
"       </li>",
"       <li>",
"        McCarron LT. McCarron Assessment of Neuromuscular Development (revised ed). Common Market Press, Dallas, TX 1982.",
"       </li>",
"       <li>",
"        Bruininks RH. Bruininks-Oseretski test of motor proficiency. American Guidance Service, Circle Pines, MN 1978.",
"       </li>",
"       <li>",
"        Ayres AJ. Southern California sensory integraton tests-revised. Western Psychological services, Los Angeles, CA&nbsp;1980.",
"       </li>",
"       <li>",
"        Ayres AJ. Sensory integration and praxis test. Western Psychological services, Los Angeles, CA&nbsp;1989.",
"       </li>",
"       <li>",
"        Beery KE, Buktenica NA. Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th ed, Pearson Assessments, 2010.",
"       </li>",
"       <li>",
"        Folio MR, Fewell RR. Peabody Developmental Motor Scales, Second Edition (PDMS-2), Western Psychological Services, Los Angeles, CA 2000.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6268=[""].join("\n");
var outline_f6_7_6268=null;
var title_f6_7_6269="FTT tips for parents";
var content_f6_7_6269=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Behavioral tips for parents of children with failure to thrive (undernutrition)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Dietary advice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consumption of excessive fluid reduces the intake of solid foods. At mealtimes, offer solids before liquids. (Liquids are filling and provide fewer calories.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit juices to 4 to 8 ounces per day. Also limit intake of water and carbonated drinks - offer milk or formula instead.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Don't worry if your child wants to eat the same food every day. Variety is not important. Total calories and protein are.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Junk foods have little protein and fewer calories than some other food choices. Junk foods will not help growth; they only take up valuable space in the stomach.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Offer foods that are easy for your child to handle (eg, Cheerios&reg;, french fries, slices of banana, or peas).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Add margarine, mayonnaise, gravies, and grated cheese. For snacks, use cheese, pudding, bananas, or dried fruit.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Feeding times",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children need to eat often, not constantly. Offer something every two to three hours, to allow three meals and two to three snacks per day. Avoid snacks right after an unfinished meal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Children work well with schedules. Try to keep mealtimes and snack times about the same each day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allow one hour without food or drink (except water) before a meal to stimulate the appetite.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not make mealtime too long for your child. (Fifteen minutes is probably long enough for a toddler.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Feeding behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try to relax; feeding/eating and mealtimes should be pleasant for everyone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recognize your child's cues indicating hunger, satiety, and food preferences.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        You are responsible for deciding what food your child is offered (with consideration for your child's preferences); your child decides how much to eat.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid battles over eating. Encourage your child, but avoid forced feeding, threatening, bribing, or punitive approaches. Instead, use positive reinforcement (eg, praise for eating well).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do not withhold food as a form of punishment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allow your child to feed himself or herself. Try very small amounts at first. Offer seconds later. Expect messiness and be prepared for easy clean-up (bibs, newspaper under high chair, etc).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some babies want to control the spoon - for such babies, use two spoons, one for the baby to control and one for you to use to feed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Feeding environment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Try to eat together as a family. Good eating behavior can be modeled, and young children like to mimic older siblings and parents.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limit possible distractions during meals (eg, television).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Make sure your child can reach the food. (Use a high chair, booster seat, telephone book, or small table.)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Bithoney WG, Dubowitz H, Egan H. Failure to thrive/growth deficiency. Pediatr Rev 1992; 13:453.",
"       </li>",
"       <li>",
"        Frank DA, Zeisel SH. Failure to thrive. Pediatr Clin North Am 1988; 35:1187.",
"       </li>",
"       <li>",
"        Frank D, Silva M, Needlman R. Failure to thrive: Mystery, myth and method. Contemp Pediatr 1993; 10:114.",
"       </li>",
"       <li>",
"        Texas Children's Hospital (www.texaschildrenshospital.org/Parents/TipsArticles/AcrobatDisplay.aspx?fid=145).",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6269=[""].join("\n");
var outline_f6_7_6269=null;
var title_f6_7_6270="Recurrence of insulinoma";
var content_f6_7_6270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82017&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Recurrence rate of insulinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 284px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recurrence rate of insulinoma after initial curative surgery in 196 patients in the Mayo Clinic cohort (1927 to 1986). The likelihood of recurrence was greater in those patients with multiple endocrine neoplasia syndrome type 1 (21 versus 7 percent at 20 years).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of F John Service, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6270=[""].join("\n");
var outline_f6_7_6270=null;
var title_f6_7_6271="Generalized cutaneous blistering disorders";
var content_f6_7_6271=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60255%7EDERM%2F82490%7EDERM%2F67630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60255%7EDERM%2F82490%7EDERM%2F67630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of generalized cutaneous blistering disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous pemphigoid",
"       </td>",
"       <td>",
"        Tense bullae, urticarial papules and plaques; mucous membrane involvement in up to 30 percent of cases",
"       </td>",
"       <td>",
"        H&amp;E: subepidermal blister with eosinophils; DIF: linear basement membrane zone deposition of IgG and C3",
"       </td>",
"       <td>",
"        IIF: IgG anti-BP antigen 180 and 230",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pemphigus vulgaris",
"       </td>",
"       <td>",
"        Flaccid vesicles and erosions on skin and mucous membranes, desquamative gingivitis; scalp involvement common",
"       </td>",
"       <td>",
"        H&amp;E: intraepidermal blister formation, acantholysis; DIF: intercellular epidermal IgG deposition involving lower epidermis",
"       </td>",
"       <td>",
"        IIF: intercellular IgG staining of skin substrate, anti- desmoglein 3 IgG",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pemphigus foliaceus",
"       </td>",
"       <td>",
"        Flaccid vesicles and erosions; no mucous membrane involvement",
"       </td>",
"       <td>",
"        H&amp;E: intraepidermal vesicle and acantholysis (blister is subcorneal); DIF: intercellular IgG deposition in upper epidermis",
"       </td>",
"       <td>",
"        IIF: intercellular IgG staining of skin substrate; anti-desmoglein 1 IgG",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Stevens-Johnson syndrome and toxic epidermal necrolysis",
"       </td>",
"       <td>",
"        Exudative erosions of lips, oral mucosa, eyes, genital mucosa; targetoid papulovesicles of skin, skin sloughing, and skin pain",
"       </td>",
"       <td>",
"        H&amp;E: vacuolar interface dermatitis or epidermal necrosis",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Paraneoplastic pemphigus",
"       </td>",
"       <td>",
"        Targetoid papulovesicles, erythema multiforme like cutaneous lesions; exudative erosions of lips, oral mucosal, eyes, genital mucosa",
"       </td>",
"       <td>",
"        H&amp;E: mixed histology with overlapping features of pemphigus vulgaris, erythema multiforme, and lichen planus; DIF: staining of transitional epithelium (rodent bladder)",
"       </td>",
"       <td>",
"        IIF: antibodies to multiple antigens (desmoplakins, desmogleins, bullous pemphigoid antigen 1, etc)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dermatitis herpetiformis",
"       </td>",
"       <td>",
"        Grouped papulovesicles on elbows, knees, buttocks, scalp; intense pruritus",
"       </td>",
"       <td>",
"        H&amp;E: subepidermal blister with neutrophils in dermal papillae; DIF: IgA in dermal papillae",
"       </td>",
"       <td>",
"        Elevation of serum IgA anti-epidermal transglutaminase antibodies",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Disseminated HSV/VZV",
"       </td>",
"       <td>",
"        Fever, hepatitis, CNS involvement; grouped and scattered monomorphic vesicles",
"       </td>",
"       <td>",
"        Intraepidermal blister; ballooning of keratinocyte cytoplasm and margination of chromatin to form intranuclear inclusion bodies; mixed inflammatory infiltrate",
"       </td>",
"       <td>",
"        Viral culture, Tzanck smear, DFA, PCR",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Linear IgA bullous dermatosis",
"       </td>",
"       <td>",
"        Annular or arcuate vesicles and bullae; can have mucous membrane involvement",
"       </td>",
"       <td>",
"        H&amp;E: subepidermal blister with predominance of neutrophils; DIF: linear IgA along basement membrane zone",
"       </td>",
"       <td>",
"        IIF: circulating IgA anti-basement membrane antibodies",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Epidermolysis bullosa acquisita",
"       </td>",
"       <td>",
"        Tense blisters and erosions with scarring and milia",
"       </td>",
"       <td>",
"        H&amp;E: subepidermal blisters with mixed inflammatory infiltrate of neutrophils, eosinophils, lymphocytes; DIF: broad, linear IgG along the basement membrane zone; in salt split skin, IgG stains dermal side",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Staphylococcal scalded skin syndrome",
"       </td>",
"       <td>",
"        Widespread erythema, flaccid bullae, erosions, desquamation of skin",
"       </td>",
"       <td>",
"        H&amp;E: subcorneal blister (split within the granular cell layer)",
"       </td>",
"       <td>",
"        Toxin-mediated condition; culture often negative at sites of blistering",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bullous systemic lupus erythematosus",
"       </td>",
"       <td>",
"        Other skin findings of SLE: nail fold telangiectasias, malar erythema, discoid or subacute cutaneous lupus",
"       </td>",
"       <td>",
"        H&amp;E: similar to dermatitis herpetiformis DIF: mixed features similar to bullous pemphigoid and lupus",
"       </td>",
"       <td>",
"        Antinuclear antibody test",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H&amp;E: hematoxylin and eosin pathology stain; DIF: direct immunofluorescence; IIF: indirect immunofluorescence; HSV: herpes simplex virus; VZV: varicella zoster; virusDFA: direct fluorescent antibody test; PCR: polymerase chain reaction; CNS: central nervous system; SLE: systemic lupus erythematosus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Select examples of localized cutaneous blistering disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diagnostic tests",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dermatitis",
"        </strong>",
"       </td>",
"       <td>",
"        Linear configuration if contact dermatitis.",
"       </td>",
"       <td>",
"        H&amp;E: spongiosis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Bullous tinea pedis",
"        </strong>",
"       </td>",
"       <td>",
"        Vesicles on soles of feet or between the toes.",
"       </td>",
"       <td>",
"        KOH examination demonstrating hyphae or positive fungal culture",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Fixed drug eruption",
"        </strong>",
"       </td>",
"       <td>",
"        Dusky violaceous patch, hemorrhagic bulla; may recur at same location with future drug exposures.",
"       </td>",
"       <td>",
"        <p>",
"         History",
"        </p>",
"        <p>",
"         H&amp;E: lichenoid or interface dermatitis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Erythema multiforme",
"        </strong>",
"       </td>",
"       <td>",
"        Targetoid papules on extremities and acral locations; hemorrhagic vesicles/bullae; intermittent recurrences usually associated with HSV infection.",
"       </td>",
"       <td>",
"        H&amp;E: vacuolar interface dermatitis; positive confirmation of concurrent HSV outbreak",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Friction blisters",
"        </strong>",
"       </td>",
"       <td>",
"        Most commonly seen on soles of feet or palms of hands at sites of friction.",
"       </td>",
"       <td>",
"        <p>",
"         History",
"        </p>",
"        <p>",
"         H&amp;E: intraepidermal blister",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Coma blisters",
"        </strong>",
"       </td>",
"       <td>",
"        Tense blisters at sites of pressure in comatose patients.",
"       </td>",
"       <td>",
"        <p>",
"         History",
"        </p>",
"        <p>",
"         H&amp;E: subepidermal blister and eccrine gland necrosis",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Bullous insect bites",
"        </strong>",
"       </td>",
"       <td>",
"        Intense pruritus and erythematous papules.",
"       </td>",
"       <td>",
"        History",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Bullous disease of diabetes (bullous diabeticorum)",
"        </strong>",
"       </td>",
"       <td>",
"        Tense blisters found predominately on lower extremities. Lack of erythema or inflammation. Rare manifestation of diabetes.",
"       </td>",
"       <td>",
"        <p>",
"         H&amp;E: pauci-inflammatory subepidermal blister",
"        </p>",
"        <p>",
"         DIF: negative",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Grover's (transient acantholytic dermatosis)",
"        </strong>",
"       </td>",
"       <td>",
"        Keratotic eroded papules and vesicles on the abdomen, chest, back. Male predominance. Often worsens with heat, exercise, hospitalization.",
"       </td>",
"       <td>",
"        <p>",
"         H&amp;E: dyskeratosis and acantholysis",
"        </p>",
"        <p>",
"         DIF: negative",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H&amp;E: hematoxylin and eosin pathology stain; DIF: direct immunofluorescence; KOH: potassium hydroxide; HSV: herpes simplex virus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Blistering disorders with mucous membrane involvement",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Associated conditions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Herpes simplex virus (HSV)",
"        </strong>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Recurrent, grouped vesicles; most commonly found on lips or genitalia",
"       </td>",
"       <td>",
"        H&amp;E: intraepidermal blister; ballooning of keratinocyte cytoplasm and margination of chromatin to form intranuclear inclusion bodies; mixed inflammatory infiltrate",
"       </td>",
"       <td>",
"        Viral culture, Tzanck smear, HSV DFA, PCR",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Erythema multiforme",
"        </strong>",
"       </td>",
"       <td>",
"        Herpes simplex virus or",
"        <em>",
"         Mycoplasma pneumoniae",
"        </em>",
"        infection, occasionally drug exposure",
"       </td>",
"       <td>",
"        Mucosal erythema and erosions, most frequently involving oral cavity; target lesions on skin",
"       </td>",
"       <td>",
"        H&amp;E: vacuolar interface dermatitis, necrotic keratinocytes, subepidermal clefts and vesiculation",
"       </td>",
"       <td>",
"        HSV testing on active lesions, serology, or biopsy specimen; testing for",
"        <em>",
"         M. pneumoniae",
"        </em>",
"        infection",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Pemphigus vulgaris",
"        </strong>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Vesicles, erosions and desquamative gingivitis",
"       </td>",
"       <td>",
"        <p>",
"         H&amp;E: intraepidermal vesicle, acantholysis",
"        </p>",
"        <p>",
"         DIF: intercellular epidermal IgG deposition",
"        </p>",
"       </td>",
"       <td>",
"        IIF: intercellular IgG staining of skin substrate, IgG anti-desmoglein 3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Mucous membrane pemphigoid",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        Reflects a diverse group of subepidermal blistering disorders with mucous membranes as the primary site of involvement",
"       </td>",
"       <td>",
"        Vesicles and erosions, desquamative gingivitis; can have ocular involvement and symblepharon",
"       </td>",
"       <td>",
"        H&amp;E: subepidermal blisters; inflammatory infiltrate and DIF findings vary with subtype",
"       </td>",
"       <td>",
"        IIF: varies with subtype",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Stevens-Johnson syndrome and toxic epidermal necrolysis",
"        </strong>",
"       </td>",
"       <td>",
"        Medication, M",
"        <em>",
"         ycoplasma",
"        </em>",
"        infection",
"       </td>",
"       <td>",
"        Exudative erosions of lips, oral mucosa, eyes, genital mucosa; targetoid papulovesicles of skin, skin sloughing, skin pain",
"       </td>",
"       <td>",
"        H&amp;E: vacuolar interface dermatitis or epidermal necrosis",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Paraneoplastic pemphigus",
"        </strong>",
"       </td>",
"       <td>",
"        Underlying malignancy",
"       </td>",
"       <td>",
"        Targetoid papulovesicles; erythema multiforme-like cutaneous lesions; exudative erosions of lips, oral mucosal, eyes, genital mucosa",
"       </td>",
"       <td>",
"        <p>",
"         H&amp;E: mixed histology; overlapping features of pemphigus vulgaris, erythema multiforme, and lichen planus",
"        </p>",
"        <p>",
"         DIF: staining of transitional epithelium (rodent bladder)",
"        </p>",
"       </td>",
"       <td>",
"        IIF: antibodies to multiple antigens (desmoplakins, desmogleins, bullous pemphigoid antigen 1, etc.)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HSV: herpes simplex virus; H&amp;E: hematoxylin and eosin pathology stain; DIF: direct immunofluorescence; IIF: indirect immunofluorescence; PCR: polymerase chain reaction.",
"     <br>",
"      * Skin predominant forms of bullous pemphigoid, linear IgA bullous dermatosis, and epidermolysis bullosa acquisita may also present with mucosal involvement.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_7_6271=[""].join("\n");
var outline_f6_7_6271=null;
  